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Ischaemia-reperfusion (I/R) injury of the kidneys is a common cause of acute kidney injury 
(AKI). Th e incidence of AKI among hospitalized patients varies between 2% and 10%, and 
the mortality rate among patients undergoing renal replacement therapy in intensive care 
units may be over 50%, since the ischaemic kidney injury oft en occurs in the context of multi 
organ failure (MOF) and sepsis. Furthermore, patients suff ering from AKI have increased risk 
of developing chronic kidney disease. Currently, there is no curative therapy for I/R injury-
induced AKI. Accumulating evidence indicates a major role for haemodynamic alterations, 
oxidative stress and infl ammatory response, as well as endothelial and tubular cell injury in 
the pathophysiology of I/R-induced AKI. Th e aim of the present study was to increase our 
understanding of the cellular pathophysiological processes underlying kidney injury and repair 
and to identify novel drug targets for AKI. We therefore investigated whether caloric restriction 
(CR), adenosine monophosphate-activated protein kinase (AMPK) activation by 5-amino-4-
imidazolecarboxamide-1-β-D-ribofuranoside (AICAR), or α2-adrenoceptor (α2−AR) activation 
by α2−AR agonists could ameliorate kidney I/R injury. Th ese three treatment strategies have 
provided protection against tissue I/R injury, at least in part, through their anti-infl ammatory 
properties. An established and widely used murine model of kidney I/R injury was used.  Th e 
drugs were given intravenously at diff erent dosages, and the salutary eff ects of the various 
treatment strategies were assessed by combining biochemical measuments of kidney function, 
kidney histology and immunohistochemistry. Th e present study revealed that CR improved 
renal function, protected against the development of acute tubular necrosis and attenuated 
nitrosative stress as well as infl ammatory responses. Th ese eff ects were mediated at least partially 
through induction of endothelial nitric oxide synthase (eNOS) and peroxisome proliferator-
activated receptor-γ coactivator 1α (PGC-1α). Th e present study provided evidence that AICAR 
also ameliorated I/R-induced renal dysfunction, acute tubular necrosis, as well as monocyte/
macrophage infi ltration and oxidative stress. Th e eff ects of AICAR were dose-dependent and 
mediated mainly by AMPK activation. Finally, we were able to demonstrate that preconditioning 
with dexmedetomidine, a centrally acting α2−AR agonist, attenuated I/R injury-induced renal 
dysfunction, acute tubular necrosis and infl ammatory response partially through the p38-CD44 
pathway, whereas postconditioning with dexmedetomidine provided no tissue protection.  We 
also found that neither pre- nor postconditioning with a peripheral α2−AR agonist fadolmidine 
ameliorated kidney I/R injury, suggesting the importance of central α2−ARs. Taken together, 
the data from our experimental studies conducted in an established murine model of kidney 
I/R injury support the notion that compounds mimicking the cellular eff ects of CR, activators 
of kidney AMPK, as well as centrally acting α2−AR agonists may represent a novel therapeutic 




Acute kidney injury (AKI) is the generic term that refers to a sudden decrease in renal 
function, resulting in retention of waste products (Lameire et al., 2005). Th e incidence of AKI 
in hospitalized patients is 2--7% and in intensive care units (ICUs) even greater than 10%. 
Th e mortality and morbidity rates are high; in ICUs over half of the patients undergoing renal 
replacement therapy die and patients that survive have a high risk of developing chronic kidney 
disease (CKD)(Waikar et al., 2008). Th e best way to prevent AKI is to maintain appropriate levels 
of relative blood volume and cardiac output (CO) and avoid nephrotoxic agents. No specifi c 
medication for AKI is in clinical use (Lameire et al., 2005). One of the most common causes of 
AKI is ischaemia-reperfusion (I/R) injury. I/R injury results from impairment of oxygen (O2) and 
nutrient supply to the kidneys, as well as from accumulation of metabolic waste products. Th is, 
in turn, leads to acute tubular and endothelial cell death by apoptosis and necrosis. Th e initial 
injury is further worsened through the subsequent reperfusion period, infl ammation, damage 
by oxidative stress, endothelial cell injury and vascular dysfunction (Bonventre and Yang, 2011). 
Mitochondria seem to be the most vulnerable organs damaged by I/R injury (Hasegawa et al., 
2010).  Th e repair process may also be maladaptive and lead to incomplete tubular repair, chronic 
infl ammation and increased fi brosis in the kidneys, leading to CKD (Bonventre and Yang, 2011).
Caloric restriction (CR), without malnutrition, extends the lifespan in various species, 
including rodents and primates. It also delays the onset of age-associated phenotypes, including 
cardiovascular diseases (CVDs), cancer and diabetes (Fontana et al., 2010).  Some studies 
indicate that CR may also provide protection against ischaemic injuries (Morris et al., 2011). 
Sirtuins (silent information regulator 2 [Sir2] proteins) (SIRT1--7) are evolutionarily conserved 
nicotine adenine dinucleotide+ (NAD+)-dependent deacetylases and are known to mediate the 
health-promoting eff ects of CR (Hao and Haase, 2010; Morris et al., 2011). SIRT1 (Haigis and 
Sinclair, 2010; Hao and Haase, 2010) and induction of endothelial nitric oxide synthase (eNOS) 
(Nisoli et al., 2005) play central roles in mediating the benefi cial eff ects of CR and these two 
molecules also regulate each other, forming an interesting positive feedback loop (Nisoli et al., 
2005, Canto and Auwerx, 2012). SIRT1 activation also seems to be benefi cial in the context of 
AKI. Pretreatment with the SIRT1 activator resveratrol (trans-3,5,4’-trihydroxystilbene) (RSV) 
reduces acute  I/R injury in rats (Bertelli et al., 2002; Chander and Chopra, 2006) and activation 
of SIRT1 protects the mouse renal medulla from oxidative stress (He et al., 2010).  Nevertheless, 
it is still not clear how CR or SIRTs mediate their possible renoprotective eff ects.
Autophagy reprocesses the cell´s substances for biosynthetic or metabolic needs and is a 
general cellular response to stress (Mizushima et al., 2008). CR is known to stimulate autophagy 
(Groenendyk et al., 2010, Madeo et al., 2010), which increases SIRT1 expression and attenuates 
hypoxia-induced mitochondrial and renal damage (Kume et al., 2010). Th ere is growing evidence 
that induction of autophagy protects cells by eliminating damaged and potentially dangerous 
organelles, such as leaky mitochondria (Cybulsky, 2010).
Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a metabolic master 
switch that is also activated when cellular energy levels are low. AMPK and SIRT1 regulate each 
other in many ways.  AMPK plays an important role in the regulation of ion transport, podocyte 
functioning and diabetic renal hypertrophy in the kidneys (Hallows et al., 2010). AMPK is 
also a key regulator of lipid and glucose metabolism. Previous studies have provided evidence 
that AMPK is rapidly activated by acute renal ischaemia. However, the functional signifi cance 
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of this AMPK activation remains undefi ned. Mount et al. (2005) showed that although renal 
ischaemia activates AMPK within 1 min, the downstream target for AMPK, namely eNOS, was 
not phosphorylated. It is also unclear whether long-term pharmacological activation of AMPK 
provides protection against renal I/R injury.
AICAR (5-amino-4-imidazolecarboxamide riboside-1-β-D-ribofuranoside) is an adenosine 
analogue that directly binds to AMPK, leading to allosteric modifi cation and activation of 
AMPK. AICAR is taken up by adenosine transporters and subsequently phosphorylated to ZMP 
(5-aminoimidazole-4-carboxamide-1-β-D-furanosyl 5’-monophosphate) in the cell (Wong et al., 
2009). ZMP in turn mimics AMP in AMPK signalling (Merrill et al., 1997). Previous studies 
have provided evidence that AICAR protects against I/R injury in several tissues, such as heart 
and liver (Bullough et al., 1994, Alkhulaifi  and Pugsley, 1995, Galinanes et al., 1995, Mathew et 
al., 1995, Peralta et al., 2001). Lin et al. (2004) were the fi rst to demonstrate that combination 
therapy with AICAR and the antioxidant acetyl cysteine attenuates I/R-induced AKI. However, 
the eff ects of AICAR treatment alone on I/R-induced AKI remain unclear.
Th e alpha2 adrenoceptor (α2-AR) agonist dexmedetomidine (Dex) is in clinical use as a 
sedative for intensive care unit (ICU) patients who require only mild sedation and it also seems 
to enhance renal function in certain clinical cases (Kulka et al., 1996; Frumento et al., 2006). 
Animal studies have indicated that Dex may provide protection against ischaemic injuries by 
aff ecting various intracellular kinases, oxidant status and adhesion molecules  (Maier et al., 1993; 
Kuhmonen et al., 1997; Jolkkonen et al., 1999; Gu et al., 2011b; Ibacache et al., 2012; Kilic et al., 
2012; Tufek et al., 2013) 
Th e aim of this thesis project was to increase the knowledge of the pathophysiological 
mechanisms of I/R- induced AKI and identify new targets for drug development. We postulated 
that we could attenuate I/R-induced AKI by activating AMPK and/or other metabolic sensors, 
as well as autophagy, either through specifi c activators or through CR. We also wanted to test the 
hypothesis that α2-AR agonists may provide renoprotection through metabolic reprogramming.
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2  Review of the literature
2.1  Kidney anatomy and physiology
Mammalian kidneys develop from the intermediate mesoderm. Humans normally have two 
kidneys located retroperitoneally between the transverse processes of the thoracic 12--lumbar 3 
(T12--L3) vertebrae. Th e kidneys receive blood from the paired renal arteries and drain into the 
paired renal veins, excreting urine into a ureter that empties into the urinary bladder (Diagram 
1). Th e functions of the kidneys include fi ltration and excretion of metabolic waste products 
and regulation of fl uid, electrolyte and acid-base balances. Th e kidneys also reabsorb glucose 
and amino acids. Interstitial fi broblasts in the kidney secrete a cytokine called erythropoietin 
(EPO), which stimulates red-blood cell production and also has other biological functions. Th e 
juxtaglomerular cells in the kidneys also regulate blood pressure (BP) by secreting renin, an 
important factor of the renin-angiotensin-aldosterone system (RAS) and the proximal tubule 
cells of the kidneys produce calcitriol, which is a hormonally active form of vitamin D. Th e 
cells of the renal cortex take part in gluconeogenesis.  Various cells show diff ering metabolic 
profi les in the kidney. In the inner medulla, the cells have fewer mitochondria and are dependent 
predominantly on glycolytic metabolism. Th e tubular cells in the cortex have  abundant 
mitochondria,  suggesting that they have more oxidative metabolism and use fatty acids (an 
important energy source for kidneys), ketone bodies and lactate as metabolic substrates (Berndt, 
1976; Hallows et al., 2010; Bovee, 1986).
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Diagram 1. Structure of a nephron. Th e urine-producing functional structures of the kidney are 
called nephrons and each nephron is composed of an initial fi ltering component, the renal corpuscle, 
and a tubule specialized for reabsorption and secretion, the renal tubule. Several diff erent cell types 
are found in the kidneys, including glomerular parietal cells and glomerular podocytes, proximal 
tubular brush-border cells, Loop of Henle thin segment cells, thick ascending limb cells, distal tubular 
cells, collecting duct cells, interstitial cells, and endothelial and smooth-muscle cells in the renal 
arteries and their branches.
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2.2  Acute kidney injury
AKI is the generic term for a sudden decrease in renal function, resulting in retention of 
nitrogenous (urea and creatinine) and non-nitrogenous waste products. Frequently, this situation 
is also accompanied by metabolic disturbances, such as metabolic acidosis and hyperkalaemia, 
changes in body fl uid balance and eff ects on many other organ systems. AKI can be classifi ed 
from severe (i.e. requiring dialysis) to slight increases in serum creatinine (S-creatinine) 
concentration (e.g. 44μmol/l x 2). Th e widely used Risk, Injury, Failure, Loss and End-stage 
renal failure (RIFLE)  criteria use S-creatinine and urine output to classify AKI into three severity 
categories (risk, injury and failure) and two clinical outcome categories (loss and end-stage renal 
disease) (Lameire et al., 2005, Devarajan, 2006, Choudhury, 2010, Lameire, 2013).
Th ere is no specifi c medication for AKI (Lameire et al., 2005).  AKI occurs in 2--7% of 
all patients admitted to hospital and is associated with a 2- to 15-fold increase in mortality 
(Waikar et al., 2008). Although the pathophysiology of AKI is complex and the aetiologies 
diverse, there is now accumulating evidence to indicate that hypotension, hypoperfusion, 
hypoxia, oxidative stress and renal vasoconstriction contribute to the pathogenesis (Kunzendorf 
et al., 2010). Th e causes that present as AKI are numerous and can be divided into prerenal, 
intrinsic and postrenal (Lameire et al., 2005). Intrinsic causes damage the kidneys directly 
(e.g. acute glomerulonephritis) and postrenal acute renal failure is caused by an obstruction 
in the urinary tract below the kidneys. Prerenal causes lead to true or relative hypovolaemia, 
decrease blood fl ow to the kidney and lead to ischaemia. Th e reperfusion period worsens injury 
through infl ammation and induction of oxidative stress. For example, haemorrhagic shock, renal 
transplantation or cardiovascular surgery are potential prerenal causes that may lead to true 
hypovolaemia. Reduction in the eff ective circulating volume may be due to low CO, systemic 
vasodilatation or intrarenal vasoconstriction (Lameire et al., 2005). Hypovolaemia activates 
the neurohumoral vasoconstrictive systems that attempt to maintain the BP and CO (Badr and 
Ichikawa, 1988). Th e kidney has its own autoregulation system that keeps renal blood fl ow and 
glomerular fi ltration rate (GFR) at adequate levels. Th is system functions until the mean systemic 
arterial blood pressure (MAP) drops below 75-80 mmHg (Sharfuddin and Molitoris, 2011). 
If the BP falls, the preglomerular arterioles dilate. Th is is mediated by the generation of nitric 
oxide (NO) (De Nicola et al., 1992) and prostaglandins (Dzau et al., 1984). Vasoconstriction of 
the postglomerular arterioles by angiotensin II (Ang II) also aids in preserving the glomerular 
capillary hydrostatic pressure (Lameire et al., 2005).
Th e tubuloglomerular feedback mechanism, mediated by communication between the 
macula densa and the glomerular microvasculature, preserves the GFR and fl uid delivery to the 
distal nephrons (Lameire et al., 2005). Drugs that disturb kidney autoregulation (e.g. nonsteroidal 
anti-infl ammatory drugs (NSAIDs)) can also lead to AKI (Gambaro and Perazella, 2003). 
2.2.1  Pathophysiology of ischaemia-reperfusion-induced AKI
I/R injury is a common cause of AKI (Liano and Pascual, 1996, Mehta et al., 2004) and there 
are several causes that may lead to ischaemia in the kidneys. For example anaesthesia, cardiac 
surgery, haemorrhage and gastrointestinal fl uid losses may all lead to I/R-induced AKI 
(Th adhani et al., 1996). In the beginning, all these causes lead to inadequate amounts of eff ective 
intravascular blood volume and impairment of kidney blood fl ow. Th is leads to impairment of 
O2 and nutrient supply to the kidneys, as well as to accumulation of metabolic waste products, 
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which cause cell damage. If the reperfusion period follows, it is accompanied by infl ammation 
and oxidative stress, as well as endothelial and vascular dysfunction (Bonventre and Yang, 2011). 
(Diagram 2)
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Diagram 2. Schematic picture of the pathophysiology of I/R-induced AKI (modifi ed from picture; 
AKI. Norbert Lameire, Wim Van Biesen, Raymond Vanholder. Lancet 2005; 365: 417–30). ACh denotes 
acetylcholine, Ang II angiotensin II, NO nitric oxide, O2 oxygen, SNS sympathetic nervous system, 
TXA2 thromboxane A2.
2.2.1.1 Vascular and endothelial components of injury
During I/R-induced AKI, the total blood fl ow to the kidneys is impaired, but there are also 
regional alterations in renal blood fl ow. In animal models, the blood fl ow to diff erent parts of 
the kidneys is reduced disproportionately to the reduction in total kidney perfusion (Le Dorze et 
al., 2009). It is known that I/R injury leads to enhanced vasoconstriction, endothelial-leukocyte 
interactions and activation of the coagulation system, which in turn lead to impairment of the 
microcirculation and regional ischaemia, especially in the outer medulla. Local oedema of the 
outer medulla, as a result of ischaemic injury, further decreases the blood fl ow. Th e vascular 
endothelial and smooth-muscle cells play crucial roles in this vascular dysfunction (Bonventre 
and Yang, 2011). Th e endothelial cells contribute to vascular tone, leukocyte functioning and 
smooth-muscle responsiveness (Sprague and Khalil, 2009). In I/R injury, the endothelium 
is injured and small arterioles vasoconstrict more than do vessels from the normal kidney 
in response to increased levels of circulating vasoactive substances (e.g. Ang II), as well as in 
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response to sympathetic nerve stimulation (Bonventre and Yang, 2011). Damaged endothelial 
cells also produce less NO and other vasodilatory substances and vasodilatation in response to 
these vasodilatory substances is decreased (Conger, 1983). Leukocyte-endothelial adhesion and 
leukocyte activation lead to increased amounts of vasoactive cytokines (e.g. tumour necrosis 
factor alpha [TNF-α], interleukins IL-1β, IL-6, IL-12, IL-15, IL-18, IL-32, and endothelin), which 
impair the blood fl ow even more (Bonventre and Yang, 2011).  Tubuloglomerular feedback also 
likely contributes to preglomerular arteriolar vasoconstriction, which reduces the glomerular 
forces available for fi ltration (Blantz et al., 2007).
In I/R-induced AKI, the expression of intercellular adhesion molecule 1 (ICAM-1) and 
other cell adhesion molecules (e.g. cluster of diff erentiation 44 [CD44]) on endothelial cells 
is increased, which increases the number of endothelium-leukocyte interactions, as well as 
the expression of counterreceptors on leukocytes (Kelly et al., 1996). Th is leads to activation 
of the leukocytes, obstruction of capillaries and postcapillary venules, further activation and 
transmigration of leukocytes, production of cytokines and further promotes the infl ammatory 
response (Bonventre and Yang, 2011). Endothelial damage leads to loss of the glycocalyx, 
disruption of the actin cytoskeleton, alteration of endothelial cell-cell contacts and breakdown 
of the perivascular matrix, which increase vascular permeability and loss of fl uid into the 
interstitium (Basile, 2007, Rabelink et al., 2010). Swelling of the endothelial cells may further 
impair the blood fl ow (Bonventre and Yang, 2011).
I/R injury also reduces the number of microvessels in the outer medulla. Th is may be due to 
the downregulation of angiogenic factors (e.g. vascular endothelial growth factor [VEGF]) and 
increased amount of angiogenesis inhibitors (Basile et al., 2008). Th e reduced number of vessels 
leads to chronic hypoxia (Basile, 2007), which likely further increases the tubular injury and 
development of fi brosis. Th is, in turn, may further decrease the availability of O2 and nutrients to 
the tubules, enhance tubular stress and epithelial cell injury, interfere with regenerative processes 
and lead to further fi brosis (Bonventre and Yang, 2011).
2.2.1.2 Inflammation
Infl ammation plays an important role in I/R-induced AKI and both innate and adaptive immune 
responses contribute to the pathophysiology. Th e (nonantigen-specifi c) innate component is 
responsible for the early response to injury. Neutrophils, monocytes/macrophages, dendritic cells 
(DCs), natural killer (NK) cells and natural killer T (NKT) cells all take part in this response. Th e 
adaptive component, activated by specifi c antigens, is initiated within hours and lasts several 
days aft er injury. Th e initial ischaemic injury is followed by induction of infl ammation through 
increase in several cytokines (e.g., TNF-α, IL-6, IL-1β, transforming growth factor β [TGF-β]) 
and chemotactic cytokines (chemokines) (e.g., monocyte chemotactic protein 1 [MCP-1], IL-8 
and Regulated on Activation, chemokine (C-C motif) ligand 5 [CCL5]/ Normal T cell Expressed 
and Secreted [RANTES]) produced by tubular and endothelial cells (Bonventre and Yang, 2011). 
Tubular cells also express Toll-like receptors (TLRs), complement and complement receptors, 
and costimulatory molecules, which regulate T lymphocyte activity (Jang et al., 2009). 
Chemokines recruit leukocytes at the site of injury and are also important in angiogenesis 
and fi brosis. On the other hand, they can also have anti-infl ammatory functions. Chemokines are 
induced by cytokines (TNF-α and IL-1β), complement activation, reactive oxygen species (ROS), 
the nuclear factor kappa B (NF-κB) system and TLR-related pathways. For example, chemokine 
(C-X3-C motif) [CX3C], chemokine (C-X-C motif) ligand 1 [CXCL1] (or IL-8), chemokine 
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(C-C motif) ligand 3 [CCL3] (MIP-1α) and CCL5 have been associated with pathogenesis of 
I/R-induced AKI (Akcay et al., 2009, Bonventre and Yang, 2011). Studies in humans have also 
demonstrated that the levels of the proinfl ammatory cytokines IL-6 and IL-8 in the plasma 
predict mortality in patients with AKI (Simmons et al., 2004). Increased amounts of chemokines, 
in turn, lead to infi ltration of leukocytes into the injured kidneys (Akcay et al., 2009, Bonventre 
and Yang, 2011).
Th e complement system plays an important role in the infl ammatory process in I/R- 
induced AKI. In kidneys, activation of the complement system is mediated by the alternative 
pathway (Bonventre and Yang, 2011).
Th ere are also several anti-infl ammatory factors that inhibit the infl ammatory response 
during I/R-induced AKI (Bonventre and Yang, 2011). Ischaemia increases epithelial cell haem 
oxygenase 1, which downregulates the infl ammatory response and protects against I/R injury 
(Nath, 2006).  Tamm-Horsfall protein (THP) also has protective eff ects; it seems to undergo its 
activity by downregulating the expression of TLR4 in proximal tubular cells (El-Achkar et al., 
2008). 
AKI is oft en accompanied by hepatic dysfunction and systemic infl ammation.  Studies 
in mice have shown that IL-17A is released from the small intestine aft er AKI, which leads 
to increased infl ammation and subsequent small intestine and liver injuries (Park et al., 
2011). Development of liver injury frequently leads to other extrarenal complications, such as 
respiratory failure, intestinal barrier destruction and systemic infl ammatory response syndrome 
(SIRS). Th ese secondary complications are also important causes of mortality (Elapavaluru and 
Kellum, 2007). Th e infl ammatory response associated with I/R injury also induces production 
of ROS, which in turn act as secondary messengers and harm cell organelles directly (Bonventre 
and Yang, 2011).
2.2.1.3 Reactive oxygen species
Cellular respiration and metabolism continuously generate low levels of ROS, including 
superoxide (O2-). O2- in turn acts as a precursor for potentially more dangerous ROS, such as 
hydrogen peroxide (H2O2) and hydroxyl OH- radicals. ROS monitor O2 tension and mediate signal 
transduction from membrane receptors in many physiological processes. Low concentrations of 
ROS also control vascular tone through vascular smooth-muscle cell relaxation. Normally, the 
three isoforms of vascular superoxide dismutase (SOD) eliminate small concentrations of O2- 
(Lakshmi et al., 2009).
In oxidative stress, excess ROS overwhelm the endogenous antioxidant system. Th e acute 
response initiated by I/R injury in the kidneys is characterized by increased production of ROS 
and induction of proinfl ammatory cytokines, leading to infl ammatory response and acute tubular 
necrosis (ATN) (Bonventre and Yang, 2011). ROS are known to cause renal tubule cell injury by 
oxidation of proteins, peroxidation of lipids, DNA damage and induction of apoptosis. Oxidative 
stress is also increased in humans with AKI. Th is was observed in the depletion of plasma protein 
thiols and increased carbonyl formation (Devarajan P., 2006, Sabbahy and Vaidya, 2010).
Mitochondria seem to be among the fi rst organs damaged in I/R-induced AKI (Hasegawa 
et al., 2010) and are also one of the main sources of ROS (Gutterman, 2005). Both mitochondrial 
oxidative damage and mitochondrial dysfunction play crucial roles in the pathogenesis of kidney 
I/R injury (Bonventre and Yang, 2011). (Diagram 3)
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Increased O2- can also be derived from nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases, xanthine reductase, uncoupled eNOS, the mitochondrial electron- transport 
chain (also under physiological conditions), lipoxygenases, cytochrome P450 monooxygenases 
and cyclooxygenases. Under prolonged periods of oxidative stress, the antioxidative system may 
collapse and become downregulated. Th is leads to further impaired removal of ROS (Taniyama 
and Griendling, 2003, Heistad, 2006). It is believed that the progression from AKI to CKD is 
largely driven by ROS. In line with this, pretreatment with an SOD-mimicking molecule 
decreased kidney fi brosis aft er I/R injury (Sabbahy and Vaidya, 2010).
ROS increase degradation of NO, and increased interaction of NO with O2- leads to 
formation of peroxynitrite (ONOO-). O2- and ONOO- both contribute to the development of 
endothelial dysfunction (Munzel et al., 2005). ROS also inhibit other endothelium-dependent 
vasodilators, which further increases vascular tone. Th is is likely to be especially harmful in I/R-
induced AKI, since blood fl ow to the kidney is already decreased.
Th e increased amounts of ROS also activate redox-sensitive transcription factors (Rojas et 
al., 2006; Sabbahy and Vaidya, 2010) and boost the expression of proinfl ammatory genes (Irani, 
2000). Th is leads to altered gene expression and increases the expression of proinfl ammatory 
proteins, thus also aff ecting mitochondrial biogenesis and functioning, cell proliferation, 
apoptosis and the cell cycle. ROS also induce premature senescence by activating cell-cycle 
inhibitors (Costopoulos et al., 2008, Andrades et al., 2009).
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Diagram 3. Eff ects of oxidative stress aft er AKI.
AKI = acute kidney injury; Ang II = angiotensin II; I/R = ischaemia-reperfusion; ROS = reactive 
oxygen species; SOD = superoxide dismutase;  XO = xanthine oxidase
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2.2.1.4 Tubular injury
Proximal tubule. In most animal models of I/R-induced AKI, the epithelial cell damage associated 
with I/R injury is most apparent in the proximal tubule (Bonventre and Yang, 2011). Recent 
studies using biomarkers of proximal tubule injury, such as kidney injury molecule 1 (KIM-1) 
(measured in urine) have also revealed signifi cant proximal tubule injury in humans (Vaidya et 
al., 2008). Many patients also have clear signs of tubule epithelial injury on biopsy (Bonventre 
and Yang, 2011). Another biomarker, currently in clinical use, neutrophil gelatinase-associated 
lipocalin (NGAL), is produced mainly in the distal tubule (and also in many other organs), 
but it is also fi ltered and reabsorbed by the normal proximal tubule (Vaidya et al., 2008). Th e 
initial ischaemia destroys cytoskeletal integrity and cell polarity. Th ese cytoskeletal alterations 
occur rapidly and are dependent on the severity and duration of ischaemic injury (Sutton and 
Molitoris, 1998). Th e proximal tubule brush border is damaged and polarity of the cells is lost, 
with mislocalization of adhesion molecules and other membrane proteins (e.g. Na+K+-adenosine 
triphosphatase [ATPase] and β-integrins). Cytokines induce disruption of cell-matrix adhesion, 
and cell-cell interactions at adherent and tight junctions are also damaged (Bonventre and Yang, 
2011).
Epithelial cells communicate via tight junctions and adhesion junctions. Th ese junctions are 
regulated by the cytoskeleton, which is regulated by the Rho family of guanosine triphosphatases 
(GTPases), which in turn are activated in response to ischaemia. Inhibition of some downstream 
eff ectors of Rho GTPases attenuates I/R-induced AKI (Prakash et al., 2008, Bonventre and Yang, 
2011). Heat-shock proteins (Wang et al., 2011) and autophagy (Kimura et al., 2011) seemingly 
also play crucial roles in proximal tubule cell survival aft er I/R injury in rodents.
In severe injury, only the basement membrane remains as a barrier between the fi ltrate and 
the peritubular interstitium. Th e increase in permeability leads to backleakage of glomerular 
fi ltrate from the tubular lumen to the intersitium (Bonventre and Yang, 2011). Damaged cells 
and their debris form proinfl ammatory casts together with proteins present in the tubular lumen. 
Th ese casts can obstruct the tubule,  increase intratubular pressure (Zuk et al., 2001) and can also 
be detected in the urine as a hallmark of AKI in humans (Zuk et al., 2001; Bonventre and Yang, 
2011)
Distal tubule. Distal tubular cells are more resistant to hypoxia, ischaemia, and oxidative 
injury and remain intact during I/R-induced AKI (Bonventre and Yang, 2011). Th e medullary 
thick ascending limb has a greater capacity to convert from oxidative to glycolytic metabolism 
(Bagnasco et al., 1985). Mitogen-activated protein kinase (MAPK) pathway activation, 
antiapoptotic proteins and various growth factors may also contribute to the relative resistance of 
distal tubular cells to ischaemic injury (Bonventre and Yang, 2011). 
2.2.1.5 Repair
Kidneys are capable of recovering from I/R injury that increases cell death. However, I/R-induced 
AKI can also lead to acceleration of CKD especially in humans with underlying CKD (Ishani et 
al., 2009). Th e turnover rate of human proximal tubule cells (Nadasdy et al., 1994) increases aft er 
I/R-induced AKI when cell death is increased by necrosis and apoptosis. However, this repair 
process  may also be maladaptive and I/R-induced AKI can lead to incomplete tubular repair, 
chronic tubulointerstitial infl ammation, proliferation of fi broblasts and increased formation of 
extracellular matrix (ECM) (Bonventre and Yang, 2011). For example, chronic hypoxia, resulting 
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from loss of peritubular microvessels (Basile, 2007), and chronic activation of macrophages 
(Duffi  eld, 2010), may also contribute to the development of fi brosis aft er I/R injury.
2.2.2 Current treatments
Currently, there is no specifi c medication for AKI in clinical use. Th e best way to prevent AKI is 
to take care of the relative blood volume and CO and avoid nephrotoxins. With elderly patients, 
heart-failure patients, patients with liver disease, previous renal insuffi  ciency, renal-artery 
stenosis or diabetes, renal blood fl ow and/or autoregulation  may already be decreased, which 
makes them even more vulnerable to relative hypovolaemia and nephrotoxins (Lameire et al., 
2005).  Th is suggests that all drugs that disrupt kidney autoregulation (e.g. NSAIDs, angiotensin-
converting enzyme [ACE] inhibitors and Ang II receptor blockers) should be avoided and 
plasma concentrations of nephrotoxic drugs (e.g aminoglycosides and cyclosporine) should 
be measured. Allopurinol may be useful for patients with leukaemia and lymphoma, because 
it decreases the synthesis of uric acid (Ribeiro and Pui, 2003). F orced alkaline diuresis protects 
the renal tubules in rhabdomyolysis and prevents blockage of renal tubules by uric acid or 
methotrexate (Lameire et al., 2005).
2.2.2.1 Volume expansion
In clinical studies, the overall management of patients includes the use of fl uids, which makes 
it diffi  cult to assess the therapeutic value of volume expansion alone. It is also not clear whether 
crystalloids or colloids should be used in critically ill patients (with or without AKI) ( Lameire et 
al., 2005). For example, in the Saline versus Albumin Fluid Evaluation (SAFE) trial, there were 
no diff erences between saline and albumin (Finfer et al., 2004).   Hydration prevents ATN aft er 
surgery and ATN induced by contrast media, platinum or amphotericin B (Lameire et al., 2005). 
N e vertheless, if administrated too much, volume expansion may cause pulmonary oedema, 
especially when kidney function is impaired (Lameire et al., 2005; Prowle et al., 2010)
2 .2.2.2 Drugs
Prophylaxis with N-acetylcysteine may lower the risk of contrast nephropathy (Duong et al., 
2005). However, acetylcysteine interferes with the tubular handling of creatinine directly, which 
means that in this case the decrease in S-creatinine level does not prove that acetylcysteine 
protects kidneys (Hoff mann et al., 2004). 
Loop diuretics (e.g. furosemide) have no renoprotective eff ects in patients with AKI (Schetz, 
2004; Sampath et al., 2007). H owever, mannitol may be useful in rhabdomyolysis and kidney-
transplant surgery (Schetz, 2004). Th ese observations spark interest, because loop diuretics can 
be used to increase diuresis in oliguric AKI.  Still, diuretics do not improve prognosis ( Karajala et 
al., 2009).  Dopamine is a renal vasodilator and increases urine output. It is widely used, especially 
in ICU patients. However, dopamine, or its analogues, do not protect the kidneys (Choudhury, 
2010, Zacharias et al., 2013).  Norepinephrine has also been widely studied and may have minor 
benefi cial eff ects (Choudhury, 2010). C alcium channel blockers and ACE inhibitors seem to 
off er no protection against AKI and treatment with EPO has also failed to show any advantage 
(Zacharias et al., 2013). Other treatments for AKI that are currently being investigated include 
bioartifi cial kidneys, plasma therapies and stem-cell therapies (Lameire et al., 2005, Choudhury, 
2010).
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2. 2.2.3 Supportive treatment
Th e current preventive treatment of I/R-induced AKI is summarized in Pa nel 1. In patients with 
AKI, it is important to avoid potassium, which used to cause mortality in AKI patients before 
invention of dialysis and rapid laboratory tests (Lameire et al., 2005).
Panel 1. Management priorities in patients with AKI (modifi ed from Lameire et al., 2005)
 Correct prerenal and postrenal factors
 Review medications and stop nephrotoxins
 Optimize CO and renal blood fl ow
 Restore and/or increase urine fl ow
 Monitor fl uid intake and output; measure bodyweight daily




 Expert nursing care (management of catheter care and skin in general; psychological 
support)
 Initiate dialysis before uraemic complications emerge
 Give drugs in doses appropriate for GFR
Th e daily fl uid intake of an oliguric patient should be limited and dietary sodium should 
be restricted to 2 g/day. Th e caloric requirement in AKI is high. Carbohydrate intake should be 
suffi  cient (more than 100 g/day) to avoid breakdown of endogenous protein for glucose. Th e 
protein requirements are dependent on the clinical status; 40 g/day high-quality protein can be 
given and the protein content increased if necessary (Lameire et al., 2005).
Dialysis may be necessary, because it allows larger quantities of protein to be given. Berbel 
et al. (2011) concluded that AKI patients undergoing renal replacement therapy should receive 
25-30 kcal/kg and a minimum intake of 1.5 g/kg of proteins daily.
Enteral or parenteral alimentation may be necessary in postoperative patients or in 
those with anorexia or vomiting. Th e use of essential amino acids or their keto analogues in 
postoperative or trauma patients has been suggested, but may not improve the outcome of AKI 
(Lameire et al., 2005). Hyperglycaemia is known to have many adverse eff ects; elevated blood 
glucose levels are also associated with increased occurrence of AKI aft er cardiac surgery (Song et 
al., 2013). 
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 2.2.2.4 Renal replacement therapy
Dialysis should be started before complications occur.  Th e criteria for dialysis are given in Panel 2.
 Panel 2. Proposed criteria for dialysis with AKI (modifi ed from Lameire et al., 2005)
 Oliguria: urine output < 200 ml in 12 h
 Anuria: urine output < 50 ml in 12 h
 Hyperkalaemia: potassium concentration > 6.5 mmol/l
 Acidaemia: pH < 7.0




 Plasma sodium abnormalities: concentration >155 mmol/l or <120 mmol/l
 Hyperthermia
 Drug overdose with dialysable toxin
2.2.3  Prognosis
Th e prognosis varies, depending on the stage of AKI. Th e in-hospital mortality rate with AKI 
patients has varied between 20% and 25% (Waikar et al., 2008). However, if renal replacement 
therapy is needed, the mortality rate can be as high as 66% (Waikar et al., 2008). AKI is also 
oft en accompanied by multiorgan failure (MOF) , which further increases mortality (Lameire et 
al., 2005).  A slight decline in the mortality rates of AKI has been observed in recent decades 
(Waikar et al., 2008). 
AKI is irreversible in 5% of all and in 16% of elderly  patients (Lameire et al., 2005). Many of 
these patients will eventually develop CKD (Coca et al., 2009; Hsu et al., 2009).  In children with 
AKI, kidney dysfunction develops in early adulthood (Lameire et al., 2005). Th e risk of CKD is 
higher with older patients (Ishani et al., 2009).  
2.3  Caloric restriction and underlying pathways
2.3.1  Health-promoting effects of caloric restriction and prolonged 
lifespan
It was observed  almost 80 years ago that CR, without malnutrition, prolongs the lifespan in 
several species, including yeast, fl ies, worms, fi sh, rodents and rhesus monkeys (Macaca 
mulatta [Zimmermann]) (Fontana et al., 2010). CR has positive eff ects in chronic conditions, 
e.g. cancer, neurodegenerative diseases, age-associated renal injury, obesity, diabetes, as well as 
atherosclerosis. Th e health-promoting eff ects of CR have been demonstrated in many organisms, 
including primates (Colman et al., 2009; Fontana et al., 2010). CR lasting between 3 months 
and 1 year also seems to attenuate ischaemic injuries in rodent models of cardiac and cerebral 
ischaemia (Yu and Mattson, 1999; Chandrasekar et al., 2001; Ahmet et al., 2005). On the cellular 
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level, it is known that CR reduces oxidative stress and enhances autophagy (Speakman and 
Mitchell, 2011).
Th ere are at least four pathways that have been implicated in mediating the eff ects of CR; 
1.insulin like growth factor 1 (IGF-1)/insulin signalling pathway, 2. SIRT pathway, 3. AMPK 
pathway and 4. target of rapamycin (TOR) pathway (Diagram 4) (Speakman and Mitchell, 2011). 
Budding yeast gets older’ mainly because of the accumulation of extrachromosomal 
ribosomal DNA (rDNA) circles (ERCs). It was discovered that Sir2, the fi rst SIRT family member, 
is a suppressor of ERC formation and regulates the lifespan. Th is was the fi rst time SIRTs were 
linked with the positive eff ects of CR. It was observed that increased copy numbers of the 
SIR2 gene not only increase the lifespan in yeast but also delay aging in Caenorhabditis elegans 
(Maupas) and Drosophila melanogaster (Meigen). It was concluded that Sir2 and its orthologues 
are crucial modulators in the regulation of longevity in both lower and higher organisms. Sir2 
and its homologues also mediate CR-induced extension of the yeast replicative lifespan, which 
may be diff erent under nondividing conditions (Smith et al., 2007).
Th e normal process of aging in kidneys includes structural and functional changes, e.g. 
glomerulosclerosis and tubulointerstitial fi brosis, a decrease in GFR and renal blood fl ow, and 
progressive loss of multiple tubular transport functions. CR slows down this aging process. 
SIRT1 is also expressed in the kidney and seems to be cytoprotective (Hao and Haase, 2010). 
However, its role in CR-mediated renoprotection is still unclear.
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Diagram 4. Potential molecular mechanisms of the anti-aging actions of caloric restriction in 
kidneys. AMP=adenosine monophosphate, ATP= adenosine triphosphate, AMPK= adenosine 
monophosphate kinase, eNOS= endothelial nitric oxide synthase, IGF-1=insulin-like growth factor 
1, mTOR=mammalian target of rapamycin, NAD+= nicotinamide adenine dinucleotide, NADH= 
nicotinamide adenine dinucleotide hydrogen, PGC-1= peroxisome proliferator-activated receptor-γ 
coactivator 1, ROS=reactive oxygen species, SIRT1= silent information regulator 1.
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2.3.2  Sirtuins
SIRTs are evolutionarily conserved NAD+-dependent class III histone deacetylases. Th ey also 
have monoadenosine diphosphate (ADP) ribosyltransferase activity, especially two mammalian 
SIRTs, SIRT4 and SIRT6 (Diagram 5). SIRTs regulate gene transcription, DNA repair and 
recombination, chromosomal stability and mediate the health-promoting eff ects of CR. Seven 
Sir2 homologues, (SIRT1--7), have been identifi ed in mammals. SIRT1, SIRT6 and SIRT7 are 
primarily located in the nucleus, whereas SIRT2 is found in the cytoplasm and SIRT3, SIRT4 and 
SIRT5 reside in the mitochondria (Haigis and Sinclair, 2010).
Th e activity of SIRTs is regulated diff erently in various tissues by CR. For example, Chen 
and coworkers (2008) showed recently that CR reduces SIRT1 activity in the liver, whereas SIRT1 
expression in skeletal muscle and white adipose tissue is markedly induced by CR.
SIRT1 couples protein deacetylation with NAD+ hydrolysis, generating nicotinamide 
(NAM) and 2’-O-acetyl-ADP-ribose. Th e catalytic activity of SIRTs is dependent on NAD+.
Th e intracellular NAD+/nicotinamide adenine dinucleotide hydrogen (NADH) ratio, in turn, is 
dependent on cellular energy and the redox state. SIRTS are typically activated during diff erent 
stressful states, such as CR. In most cases, this tissue- and context-specifi c activation of SIRTs 
increases cellular resistance to diff erent metabolic, oxidative and hypoxic disorders. Activation 
of SIRT1 is associated with longevity and the attenuation of metabolic disorders. In the kidney, 
SIRT1 protects cells and participates in the regulation of BP and sodium balance (Hao and 
Haase, 2010).
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Diagram 5. Actions of sirtuins. Schematic picture how sirtuins deacetylate (e.g.) proteins (Panel 
A) and have also ADP-ribosyl transferase activity (Panel B). ac=acetyl group, NAD+= nicotinamide 
adenine dinucleotide, NAM=nicotinamide, SIRT=silent information regulator.
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2.3.2.1 SIRT1
SIRT1 mediates and is also needed for mediating the benefi cial eff ects of CR (Chen et al., 2005, 
Boily et al., 2008). It mainly functions by deacetylating several targets, which include histones, 
transcription factors and enzymes (Hao and Haase, 2010).
Regulation of SIRT1 is complex. CR and conditions that cause oxidative stress and DNA 
damage increase the expression of SIRT1 (Cohen et al., 2004, Rodgers et al., 2005).  High-fat 
diets, insulin resistance, high glucose and senescence, in turn, decrease the expression of SIRT1. 
Th e increase in SIRT1 expression in response to acute stress is controlled and counterbalanced in 
many ways and involves regulation at the promoter, messenger RNA (mRNA) and protein levels 
(Hao and Haase, 2010).
SIRT1 enzymatic activity is associated with the consumption of NAD+ and the production 
of NAM, which in turn, inhibits its catalytic activity. Nicotinamide phosphoribosyltransferase 
NAMPT lowers the concentration of inhibitory NAM and increases the levels of NAD+. NAD+ 
also increases SIRT1 expression (Morris et al., 2011).
Further evidence for the health benefi ts of SIRT1 activation comes from resveratrol (RSV) 
and its analogue studies (Chen et al., 2009; Della-Morte et al., 2009). Small amounts of RSV also 
occur naturally, e.g. in red grapes. However, there is no evidence that it would be benefi cial to 
humans (Morris et al., 2011).
During CR, SIRT1 helps to maintain glucose levels through stimulation of gluconeogenesis 
and depression of glycolysis in the liver. Th ese eff ects are mediated through deacetylation and 
activation of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) and forkhead 
box protein O1 (FOXO1) (Rodgers et al., 2005).  SIRT1 also represses peroxisome proliferator-
activated receptor-γ (PPAR-γ) in white adipose tissue and thus mobilizes fatty acids during CR 
(Picard et al., 2004). Th ere are ongoing clinical trials with SIRT activators. It is hoped that they 
will aid in maintaining glucose levels of diabetic patients within a reasonable range, which would 
be benefi cial for the kidneys as well (Hao and Haase, 2010).
SIRT1 plays a crucial role in the regulation of vascular tone. It decreases the amount of Ang 
II type 1 (AT1A) receptors (Miyazaki et al., 2008) and increases vasodilation by deacetylating 
eNOS (Mattagajasingh et al., 2007). Th e latter increases endothelial NO levels. In line with 
this, inhibition of endothelial SIRT1 leads to decreased levels of NO and impaired vasodilation 
(Mattagajasingh et al., 2007).
2.3.2.2 SIRT1 and the kidney
In rodents, CR increases the SIRT1 levels in multiple tissues, including the kidney (Cohen et 
al., 2004, Rodgers et al., 2005). CR is also associated with less injury in age-related and diabetic 
nephropathy models (Nangaku et al, 2005). Th is is probably due to a combination of systemic 
and local eff ects that includes improved glucose and lipid metabolism, decreased amounts of 
advanced glycosylation end products (AGEs), ROS reduction, increase in NO bioavailability and 
attenuation of Ang II (Hao and Haase, 2010). SIRT1 is likely to be one of the key signal molecules 
at the cellular level. In line with this, mice with complete SIRT1 defi ciency fail to adapt to CR 
(Chen et al., 2005). Interestingly, Kume et al. (2010) also recently showed that CR protected 
against hypoxia in aged kidneys through SIRT1-dependent mitochondrial autophagy.
He et al. (2010) also recently showed the importance of SIRT1 in the kidney during 
oxidative stress in which activation of SIRT1 protected the mouse renal medulla from oxidative 
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injury. In the heart, SIRT1 attenuates I/R injury through activation of antioxidant mechanisms 
and downregulation of proapoptotic molecules (Hsu et al., 2010; Nadtochiy et al., 2011a, 2011b).
SIRT1 activation enhances resistance to apoptosis in human embryonic kidney cells (Cohen 
et al., 2004). Activation of SIRT1 also protects cardiac cells, neurons and cells in the pancreatic 
islets aft er ischaemic injuries, oxidative stress or cytokine-mediated injury (Hao and Haase, 
2010).  In the rat kidney, RSV treatment also ameliorates I/R-induced AKI (Bertelli et al., 2002; 
Chander and Chopra, 2006). SIRT1 also protects mesangial cells from apoptosis (Kume et al., 
2007).
SIRT1 is abundantly expressed in renal medullary interstitial cells and seems to protect 
them (Hao and Haase, 2010; He et al., 2010). Th ese cells are constantly under oxidative stress, 
have relatively little blood fl ow and little O2 (Pallone, 2006). Th e results of Hao and Haase (2010) 
show that SIRT1 is also expressed in podocytes, but only low levels are found in the renal cortex. 
Furthermore, Hao and Haase showed that SIRT1 protects primary renal medullary interstitial 
cells from oxidative stress and that if a single allele of SIRT1 is deleted, it worsens the injury 
in the renal medulla aft er unilateral ureteral obstruction. Activation of SIRT1 also protects the 
kidney in this case (Hao and Haase, 2010).
SIRT1 also regulates sodium balance by decreasing the transcription of the epithelial 
sodium channel in the inner medullary collecting duct. Aldosterone, in turn, decreases the levels 
of mRNA encoding SIRT1 (Zhang et al., 2009).
2.3.2.3 SIRT3
SIRT3 has been implicated in the extension of the lifespan in humans. Its activity and expression 
are also regulated through the intracellular NAD/NADH ratio. SIRT3 levels are reduced in a 
sedentary lifestyle and elevated aft er endurance exercise, which also delayed signs of senescence 
in patients over 65 years of age (Pillai et al., 2010). SIRT3 is enriched in the kidneys, but its role 
in (patho)physiological processes in the kidneys is unclear (Palacios et al., 2009).
In the murine liver and kidney, SIRT3 is expressed in two diff erent isoforms: the long form 
(44 kDa) and the short form (28 kDa). Th e long form is mainly located in the mitochondria and 
is the primary mitochondrial deacetylase. Numerous mitochondrial proteins have already been 
recognized as substrates of SIRT3 (Bao et al., 2010).
Ang II regulates infl ammation, cell growth and proliferation. Disruption of the AT1A 
receptor increases the lifespan in mice. Th e positive eff ects of knocking out Ang II signalling in 
kidneys seem to be mediated through induction of NAMPT and SIRT3, and subsequent boosting 
of mitochondria (Benigni et al., 2009). In line with this, the absence of SIRT3 leads to marked 
reduction in adenosine triphosphate (ATP) (Ahn et al., 2008).
In the heart, SIRT3 protects cardiomyocytes from oxidative stress by activating transcription 
factors and increasing the expression of antioxidants (Chen et al., 2013). Exogenous NAD, at 
least in neurons and cardiomyocytes, could probably boost the activity of SIRTs and thus protect 
cells (Pillai et al., 2010).
2.3.2.4 NAMPT
NAMPT is the rate-limiting enzyme in the NAD+ salvage pathway, which means that it plays a 
critical role in the regulation of SIRT1 activity. It lowers the concentration of inhibitory NAM 
and increases the levels of NAD+, which in turn increases the activity of SIRT1. NAD+ is also 
consumed by other reactions that do not involve SIRTs (Hao and Haase, 2010). CR increases 
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both NAMPT and SIRT1 activities. NAMPT exists in intracellular and extracellular forms 
(iNAMPT and eNAMPT). eNAMPT is found in plasma and also regulates glucose homeostasis 
(Fukuhara et al., 2005). Patients with CKD have increased serum levels of NAMPT, which may 
also contribute to fi brogenesis (Yilmaz et al., 2008).  
2.3.3  AMPK
AMPK is a ubiquitously expressed heterotrimeric kinase that acts as a highly conserved 
ultrasensitive energy sensor and participates in the regulation of energy-generating and energy-
consuming pathways. AMPK regulates cellular energy metabolism, cellular nutrient (glucose and 
fatty-acid) uptake, protein synthesis, gene transcription, infl ammation, ion transport, autophagy, 
cellular polarity and NO synthesis (Hallows et al., 2010).
AMPK consists of a catalytic α subunit and regulatory β and γ subunits. Each of these 
subunits exists as multiple isoforms (α1, α2, β1, β2, γ1, γ2, γ3)(Oakhill et al., 2009). Th is gives rise to 
12 diff erent heterotrimer combinations, and splice variants further increase the diversity. AMPK 
is also found in the rat kidney, where the α1 and β2 subunits are predominant and the γ1 and γ2 
subunits are also expressed (Cammisotto et al., 2008). Mouse kidneys show the same type of 
distribution, except that β1 is predominant (Hallows et al., 2010).
Exercise, CR and ischaemia decrease the level of ATP and increase the cellular concentrations 
of AMP. AMP binds to the γ subunit of AMPK and activates it (Scott et al., 2004). However, 
AMP also activates AMPK by other means (Kahn et al., 2005). Binding of AMP allows AMPK 
to be further phosphorylated, which increases its activity by approximately 100-fold (Hawley et 
al., 1995).  AMP binding also inhibits dephosphorylation of AMPK by protein phosphatases, 
which may be the main mechanism by which AMP binding causes increased phosphorylation of 
AMPK (Sanders et al., 2007). High amounts of ATP inhibit all the above-mentioned mechanisms 
(Hardie and Hawley, 2001). Activated AMPK increases energy production and decreases energy 
consumption by phosphorylating its downstream targets (Hallows et al., 2010).
In the kidneys, AMPK participates in the regulation of energy metabolism, ion transport, 
podocyte functioning, renal hypertrophy, ischaemia, infl ammation and diabetes (Hallows et 
al., 2010). AMPK regulates the functioning of many ion transporter proteins, which consumes 
large amounts of energy in the kidney (Hallows, 2005). In the inner medulla, cells have fewer 
mitochondria and their metabolism is mainly glycolytic (Meury et al., 1994).  In contrast, the 
tubular cells in the cortex have abundant mitochondria, more oxidative metabolism and use fatty 
acids, ketone bodies and lactate as metabolic substrates (Balaban and Mandel, 1988).
In endothelial cells, AMPK regulates fatty-acid oxidation, NO production, infl ammation 
and angiogenesis. It has been proposed that this may contribute to decreased atherogenesis and 
improved endothelial functioning (Fisslthaler and Fleming, 2009). For example, shear stress 
(Chen et al., 2009), ATP levels (Mount et al., 2005), various hormones (Chen et al., 2003, 2009), 
vasoactive substances (Mount et al., 2008) and ROS (Zou et al., 2003) regulate AMPK activity in 
endothelial cells.
2.3.3.1 LKB1 and other AMPK regulators
Liver kinase B1 (LKB1) is one of at least three potential upstream AMPK kinases (Woods et al., 
2003) and is also expressed in the kidney (Denison et al., 2009). It phosphorylates a threonine 
residue (Th r172) on the catalytic α subunit of AMPK (Sanders et al., 2007). LKB1 has a long 
(LKB1L) and a short (LKB1S) splice variant; LKB1L is the variant found in the kidneys (Denison 
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et al., 2009). AMP does not activate the LKB1 complex itself, but makes AMPK a better substrate 
for LKB1 (Sanders et al., 2007).  It also activates 13 other downstream kinases that are collectively 
called AMPK-related kinases (ARKs). Th eir functions are incompletely understood (Alessi et 
al., 2006). It has been suggested that LKB1 may be constitutively active and that increase in the 
AMP/ATP ratio activates AMPK by making the already phosphorylated AMPK resistant to the 
activity of protein phosphatases (Sanders et al., 2007).
 Th e calcium/calmodulin-dependent kinase kinases (CaMKKs) are another class of AMPK 
activators, they also phosphorylate Th r172 on the α subunit of AMPK. Regulation of AMPK by 
CaMKKβ is regulated in response to changes in calcium concentration. Th e AMP/ATP ratio does 
not aff ect this regulation (Hurley et al., 2005). In some cells, TGF-β-activated kinase1 (TAK-1) 
may be an upstream kinase of AMPK (Xie et al., 2006). 
In the kidneys, ischaemia increases the AMP/ATP ratio and activates AMPK within 1 
min. Aft er 5 min, AMPK is activated even more. Aft er the acute phase of I/R injury, AMPK is 
mainly activated in the cortical tubules (Mount et al., 2005). Th e physiological relevance of this 
activation is not clear.
Th e downstream targets of AMPK are still not clear, at least not in the ischaemic kidney, 
since it does not appear to phosphorylate eNOS (Mount et al., 2005).  Th e upstream AMPK 
kinase(s) in the ischaemic kidney are still not known. Th e role of AMPK activation may also 
diff er between the ischaemia and reperfusion periods. In the heart, AMPK is activated during 
ischaemia and this activation seems to be benefi cial in most situations (Russell et al., 2004; Arad 
et al., 2007). However, in acute stroke activation of AMPK seems to be harmful (Li et al., 2007) . 
Th e net eff ect of AMPK activation is strongly dependent on tissue and timing.
Dietary salt, diabetes, adiponectin and ischaemia also regulate AMPK in the kidney (Hallows 
et al., 2010). Adiponectin activates AMPK in the podocytes and thus reduces albuminuria 
(Cammisotto and Bendayan, 2008). In the tubular cells, it also activates AMPK and reduces 
glycogen accumulation (Cammisotto et al., 2008). Reduced AMPK activity also contributes to 
the pathogenesis of diabetic renal hypertrophy (Lee et al., 2007). 
Diabetes and high glucose levels decrease AMPK activity in the kidneys (Cammisotto et al., 
2008). Th is may also be related to decreased adiponectin levels (Lee et al., 2007) and/or activation 
of the mammalian target of rapamycin (mTOR) pathway (Guo and Zhao, 2007). Hyperglycaemia 
also deactivates LKB1 (Lieberthal and Levine, 2009). On the other hand, it is not known how the 
AMPK activators aff ect renal gluconeogenesis; e.g. in the liver, metformin (which is known to 
activate AMPK without an increase in AMP/ATP –ratio) reduces it (Lee et al., 2010). Metformin 
seems also provide some renoprotection against I/R kidney injury in mice (Seo-Mayer et al. 
2011).
AMPK activity in the kidneys changes with age (Zhou et al., 2009).  Jin et al. (2004) showed 
that older rats seem to have more phosphorylated AMPK (AMPK-P), but the total amount of 
AMPK is lower. In young rats, induction of oxidative stress caused a two-fold increase in the 
expression of active AMPK. In aged rats, there was no change in AMPK phosphorylation (Jin et 
al., 2004, Percy et al., 2009).
2.3.3.2 AICAR
AICAR is an adenosine analogue and has a short half-life. It binds to AMPK, which causes 
allosteric modifi cation and activates AMPK. In cells, AICAR is phosporylated to ZMP which 
in turn acts similarly as AMP and activates AMPK by binding to its γ subunit (Merrill et al., 
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1997). Th is allosteric activation also increases AMPK affi  nity for upstream AMPK kinases, which 
phosporylate AMPK at αTh r172. Th is phosporylation by upstream kinases is responsible for most 
AMPK activity (Gaskin et al., 2009). In a canine model of autologous renal transplantation, 
combination therapy with the AMPK activator AICAR and the antioxidant N-acetyl cysteine 
attenuates I/R injury ( Lin et al., 2004). Th e relative contributions of these two drugs to 
renoprotection are unclear. In the 1980s and 1990s, AICAR was studied as a possible candidate 
for diminishing cardiac injury during coronary-artery bypass graft ing (Holdright et al., 1994), 
but this development project was stopped  due to adverse eff ects (increased serum uric acid 
levels and crystalluria) and development of other treatments.
AICAR seems to suppress the production of ROS (Kim et al., 2008), inhibits 
proinfl ammatory NF-κB signalling (Katerelos et al., 2010) and inhibits infl ammation in mouse 
mesangial cells (Peairs et al., 2009) through AMPK activation. However, it also   employs several 
other mechanisms of activity that may be independent of the activation of AMPK.
AICAR inhibits cytokines in adipose tissue (Lihn et al., 2004) and also prevents 
postischaemic leukocyte rolling and adhesive interactions with endothelial cells, thus attenuating 
reperfusion injury (Gaskin et al., 2007, 2009). AICAR is also known to increase production of 
NO in human aortic endothelial cells (Morrow et al., 2003). 
In the renal proximal tubules, I/R injury is known to damage predominantly mitochondria 
(Hasegawa et al., 2010). Long-term treatment with AICAR increases muscle mitochondrial 
content. Th e probable route of this activity is activation of AMPK and subsequent activation of 
PGC-1α (Winder et al., 2000), which is an important regulator of mitochondrial biogenesis and 
functioning (Gerhart-Hines et al., 2007, Spiegelman, 2007). 
AICAR increases glucose uptake into the muscles and decreases the blood glucose levels 
(Holmes et al., 1999). Strict glycaemic control is benefi cial for critically ill patients, but its eff ects 
on the kidneys aft er I/R injury are not as well documented. 
AICAR is also known to increase the expression of human microsomal fatty-acid omega-
hydroxylase CYP4F2 (cytochrome P450, family 4, subfamily F, polypeptide 2). Th ese fatty- acid 
hydroxylases remove excess fatty acids that can disrupt mitochondrial functioning (Hsu et 
al., 2010). AICAR also increases adiponectin gene expression (Lihn et al., 2004) and there is 
evidence that adiponectin also activates AMPK (Yamauchi et al., 2002; Wu et al. 2003). 
AICAR inhibits autophagy by a mechanism independent of AMPK activity and inhibits the 
proteosomal degradation of proteins by an AMPK-dependent mechanism (Viana et al., 2008). 
AICAR pretreatment also protects cardiomyocytes by inhibiting endoplasmic reticulum (ER) 
stress (Terai et al., 2005).
2.3.4  AMPK and SIRT1 regulate each other
AMPK and SIRT1 regulate each other and share many common target molecules (Ruderman 
et al., 2010). SIRT1 seems to increase the activity of LKB1 in human embryonic kidney 293T 
cells (and presumably also in others), which in turn activates AMPK (Lan et al., 2008). On the 
other hand, activation of AMPK apparently increases transcription of NAMPT which in turn 
increases the NAD+/NADH ratio and decreases the concentration of NAM, both of which lead 
to activation of SIRT1 (Fulco et al., 2008). It has also been suggested that AMPK may be able to 
alter the NAD+/NADH ratio and activate SIRT1 independently of NAMPT (Canto et al., 2009). 
One of the common targets for AMPK and SIRT1 is PGC-1α, of which phosphorylation by 
AMPK makes it more prone to deacetylation by SIRT1. Th is enhances its ability to activate its 
own promoter (Terai et al., 2005).
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2.3.5  mTOR
mTOR regulates protein translation and is an important integrator and transducer of intracellular 
signalling pathways. Some studies indicate that the life-extension benefi ts of CR may also be 
regulated through the mTOR pathway (Bishop and Guarente, 2007, Kennedy et al., 2007)). In 
kidneys, increased expression of mTOR prevents I/R injury (Ma et al., 2009). I/R-induced AKI 
also alters the transcription of several mTOR pathway-associated genes (Grigoryev et al., 2006).
Activation of the mTOR pathway is also associated with renal hypertrophy and is apparently 
activated under conditions in which AMPK activity is decreased, such as diabetes and high 
glucose levels (Hallows et al., 2010).
2.3.6  eNOS and nitric oxide
Endothelum-derived NO maintains vascular tone, functions as a neurotransmitter, mediates 
cellular defence and regulates mitochondrial functioning and amount of ROS. NO is also an 
important antiatherosclerotic molecule, due to its anti-infl ammatory, antiapoptotic, antiplatelet 
and antiproliferative activities. NO has been implicated in many CVDs and almost all known 
CVD risk factors appear to be associated with decreased endothelial generation of NO (Moncada 
and Higgs, 2006; Pechanova and Simko, 2007).
NO is generated by the enzyme nitric oxide synthase (NOS). Th ree isoforms of NOS have 
been identifi ed: neuronal (nNOS) or NOS1, inducible (iNOS) or NOS2 and endothelial (eNOS) 
or NOS3. nNOS is expressed in neurons and eNOS  in endothelial cells, cardiac myocytes and 
blood platelets. Cytokines induce iNOS, which is not expressed constitutively. eNOS generates 
NO and L-citrulline from L-arginine, O2 and NADPH (Govers and Rabelink, 2001).
NO is a free radical. It has one unpaired electron in the highest orbital and thus  reacts 
rapidly with other molecules containing unpaired electrons. Th e haem group of haemoglobin 
acts as an intravascular scavenger and reacts normally with endogenous NO. Th e half-life of NO 
in vivo is less than 1 s, because normally NO diff uses rapidly into red-blood cells, where it is 
converted into nitrate. However, if O2- and NO are formed within a few cell diameters of each 
other, they will form the free radical, ONOO- (Munzel et al., 2005).
CR-induced increase in eNOS activity promotes mitochondrial biogenesis (Nisoli et al., 
2005), and Canto and Auwerx (2012) recently showed that eNOS is also induced by SIRT1 
deacetylation (Canto and Auwerx, 2012). On the other hand, eNOS also induces SIRT1 gene 
expression during CR, forming a positive regulatory loop (Nisoli et al., 2005; Canto and Auwerx, 
2012). eNOS-Ser1177 is also a target of AMPK. Nevertheless, eNOS is not phosphorylated in the 
kidneys during acute ischaemia (Hallows et al., 2010, Mount et al., 2005).
2.3.7  Angiogenesis
Kidney I/R injury reduces the number of microvessels in the outer medulla  possibly due to 
the downregulation of angiogenic factors (e.g. VEGF) and increased amount of angiogenesis 
inhibitors. Th e reduced number of vessels leads to chronic hypoxia, which likely further increases 
the tubular injury and development of fi brosis (Bonventre and Yang, 2011).
In damaged tissues, the subsequent process of neovascularization (angiogenesis) is regulated 
by various signals that are mediated through transmembrane receptor tyrosine kinases and 
nonreceptor tyrosine kinases (Maulik, 2004). On the other hand, CR also increases angiogenesis 
through circulating factors (Csiszar et al., 2013), and SIRT1 apparently plays a crucial role in 
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this process (Potente and Dimmeler, 2008). In line with this, the SIRT1 activator RSV seems to 
have both pro- and antiangiogenic eff ects, depending on the situation (Chen and Tseng, 2007). 
Chemokines (Frangogiannis, 2007) and thrombospondins (TSPs) (Hugo and Daniel, 2009) are 
important regulators of angiogenesis and it is known that I/R-induced AKI increases the amount 
of TSPs in the kidneys (Hugo and Daniel, 2009).
2.4  Autophagy
Autophagy reprocesses cellular substances for biosynthetic or metabolic needs and is a general 
cellular response to stress (Mizushima et al., 2008). It enables recycling of macromolecules 
to provide nutrients and energy. In this process, portions of the cytoplasm are sequestered 
within vesicles called autophagosomes, which are then delivered to lysosomes for degradation 
(Rubinsztein et al., 2011). Formation and elongation of autophagosomes is a complex process. 
However, the elongation phase involves the protein microtubule-associated protein 1 light chain 
3/autophagy-related protein 8 (MAP1-LC3/Atg8), which is further processed to LC-3B (LC3-
II) and remains in completed autophagosomes until fusion with the lysosomes. Th e specifi c 
association of LC3-II with autophagosomes makes it a very good marker for studying autophagy 
(Ravikumar et al., 2010).
CR stimulates autophagy (Madeo et al., 2010; Groenendyk et al., 2010) and SIRT1 seems 
to mediate this eff ect (Rubinsztein et al., 2011). Although the exact mechanism is still unclear, 
SIRT1 is known to deacetylate several autophagy genes (atg5, atg7 and atg8) (Lee et al., 2008). 
Kume et al. (2010) recently proposed that SIRT1 promotes autophagy through FOXO3, which 
is an important transcription factor (Kume et al., 2010). Atg genes (e.g. Beclin and LC-3B) and 
proteins are also crucial factors in the molecular machinery of autophagy in kidneys (Periyasamy-
Th andavan et al., 2009).
Other factors linked with the regulation of autophagy include the α2 agonist clonidine 
(Williams et al., 2009) and p38 MAPK (Tang et al., 2008).
Mitochondrial oxidative damage and mitochondrial dysfunction play crucial roles in 
the pathogenesis of kidney I/R injury (Bonventre and Yang, 2011). Th ere is growing evidence 
that induction of autophagy protects cells by eliminating damaged and potentially dangerous 
organelles, such as leaky mitochondria (Cybulsky, 2010; Kume et al., 2010) and could thus also 
provide protection against I/R-induced AKI. In line with this, Finckenberg et al. (2011) recently 
showed that also CR protects against Ang II-induced mitochondrial remodelling and cardiac 
hypertrophy through induction of autophagy. However, these results should still be interpreted 
with caution, because induction of autophagy protected cells in some cases, at least in cardiac 
I/R injury, but too much induction may even be harmfull (Gustafsson and Gottlieb, 2009). 
Depending on the level of cellular stress, autophagy can either directly induce cell death or act as 
a protective mechanism of cell survival (Periyasamy-Th andavan et al., 2009).
2.5  Alpha2 adrenoceptors and their agonists
All catecholamine receptors belong to the superfamily of G protein-coupled receptors, which 
means that they transduce signals from extracellular ligands to cellular eff ector molecules via 
guanine nucleotide-binding proteins (G proteins). Th e activity of adrenaline and noradrenaline 
(NA) are mediated via adrenergic receptors, which are divided into α- and β-adrenoceptors (α- 
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and β-ARs) according to their activity in smooth-muscle relaxation. α-ARs are further divided 
into α1- and α2-ARs. It was fi rst suggested that α2-ARs would be presynaptic (inhibiting NA 
release) and α1-ARs postsynaptic (stimulatory end-organ responses). However, it is now known 
that there are also postsynaptic α2-ARs in tissues. Aft er identifi cation of selective drugs for α1- 
and α2-ARs, the division of adrenoceptors into subtypes was based on pharmacological criteria. 
Th e α1-ARs were defi ned as those activated by phenylephrine and prazosine and α2-ARs as those 
activated by clonidine and medetomidine and antagonized by yohimbine and idaxozan. Th e 
subclassifi cation of ARs is based on a molecular biological classifi cation. Th e α1-, α2- and β-ARs 
are each divided into three subtypes. It is now known that three human genes encode unique 
human α2-AR subtypes (α2A, α2B,  α2C) and that α2D-ARs (found in bovines, guinea pigs, rats 
and mice) are species variants or homologues of  human α2A-AR ( Haapalinna, 2006).
α2-ARs are found ubiquitously in the central, peripheral and autonomic nervous systems, as 
well as in vital organs and blood vessels, and mediate many of the biological eff ects of endogenous 
adrenaline and NA ( Kaur and Singh, 2011). Receptors situated in the given neuron, responding 
to transmitters released by the same neuron, are called autoreceptors. Th e best known role for 
α2-ARs is the (auto)regulation of NA release, which occurs in many neurons. However, there 
are also α2-ARs on various neurons other than noradrenergic neurons (e.g. dopaminergic, 
serotonergic, histaminergic and cholinergic) and activation of these ‘heteroreceptors’ decreases 
the fi ring rate and neurotransmitter release from these neurons (Haapalinna, 2006).
Human and rat kidneys contain all three types of α2-AR (Cussac et al., 2002), and rats also 
have α2D-ARs, which is a rodent species variant of human α2A-AR (Lehtimaki et al., 2008). 
Studies with isolated perfused kidneys show that rat renal plasma membranes contain both α1- 
and α2-ARs in a ratio of approximately 1:3 (Schmitz et al., 1981).  Meister et al. (1994) showed 
that α2A/D and α2C receptor mRNAs are found in the inner medulla associated with collecting 
tubules and α2B receptor mRNA in the proximal tubules in the outer medulla radiating into 
the cortex (Meister et al., 1994). Huang et al. (1996) also detected α2B-ARs in the basolateral 
membrane of the proximal convoluted and straight tubules (Huang et al., 1996).  In rat proximal 
tubular cells, the α2B-AR is coupled with G protein, and its stimulation by Dex inhibits the 
accumulation of cyclic AMP (cAMP) (Cussac et al., 2002). In other cases, α2-AR-coupled G 
proteins cause membrane hyperpolarization via opening of K+ channels and inhibiting Ca2+ 
infl ux. Consequently, α2-ARs have several important physiological functions (Lehtimaki et al., 
2008).
Th e systemic eff ects of α2-ARs include hypotension, bradycardia, sedation, analgesia and 
decrease in intraocular pressure (Haapalinna, 2006). Dex is a highly selective α2-AR agonist 
(Hamasaki et al., 2002) and has eight times higher affi  nity for α2-AR than does clonidine (Kaur 
and Singh, 2011). Neither clonidine nor Dex is totally selective for any one of the α2-AR subtypes, 
but Dex seems to have higher α2A-AR and α2C-AR affi  nity than clonidine. Th e sedative activity 
of Dex comes mainly through the α2A-ARs of the locus coeruleus of the brain stem and analgesic 
activity through the α2A-ARs of the spinal cord. In the heart, α2-AR agonists decrease tachycardia 
(through blocking of the cardioaccelerator nerve) and induce bradycardia via α2A-AR (through 
vagomimetic activity). In peripheral blood vessels, α2-AR agonists cause sympatholysis-mediated 
vasodilatation and smooth-muscle cell receptor-mediated vasoconstriction (Kaur and Singh, 
2011). Kawano et al. (2012) have recently shown that Dex directly inhibits vascular KATP channels, 
which seems to be an underlying mechanism of Dex-induced peripheral vasoconstriction.
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2.5.1  Dexmedetomidine
Dex has sedative, analgesic and sympatolytic properties (Mantz et al., 2011). Th ere are also some 
notions that Dex protects tissues, including kidneys, against ischaemic injuries in animal models 
(Maier et al., 1993; Kuhmonen et al., 1997; Jolkkonen et al., 1999; Gu et al., 2011b; Mantz et 
al., 2011; Kilic et al., 2012; Ibacache et al., 2012; Tufek et al., 2013). It is already in clinical use 
as a sedative for ICU patients who require only mild sedation and also seems to enhance renal 
function in some clinical cases (Kulka et al., 1996; Frumento et al., 2006). Its sedative eff ect is 
based on the reduction of the activity of the NAergic neurons in the locus coeruleus. However, 
it also has other systemic and haemodynamic eff ects, including decreased heart rate (HR) and 
lowered BP. Its sympatolytic activity is mediated via central and peripheral mechanisms and it 
also binds to α2 receptors in the spinal cord, which enhances its analgesic eff ect. A great advance 
in its clinical use (as a sedative) is that Dex maintains the patient´s respiratory drive quite well 
(Coursin et al., 2001).
Th e distribution phase of Dex is fast (distribution half-life 5–10 min). Th e terminal half-
life is approximately 2–3  h. Dex is highly protein-bound (94%), and the steady-state volume 
of distribution is 1.33  l/kg. Dex is almost completely biotransformed in the liver through 
cytochrome P450-mediated metabolism and glucuronidation. A small amount of unchanged 
form is excreted in the urine or faeces (Bhana et al., 2000; Lee et al., 2012).
2.5.1.1 Dexmedetomidine and the kidneys
Th ere are already data showing that Dex may protect the kidneys in clinical use. At least aft er 
thoracic surgery, 24-h Dex infusion (0.4 μg kg-1 h-1)-induced diuresis and calculated creatinine 
clearance values were signifi cantly better in the Dex group than in the control group. Th e Dex 
group also received fewer diuretic agents than did the control group (Frumento et al., 2006). In 
dogs, Dex 10 μg/kg intravenous (i.v.) decreased CO by 50%. However, blood fl ow through the 
arteriovenous anastomoses and skin decreased by 70--90%, but renal blood fl ow only by 30%. 
Th e cerebral and left  ventricular blood fl ows were maintained considerably better, indicating 
that Dex causes redistribution of CO, predominantly reducing blood fl ow to the less vital organs 
and shunt fl ow (Lawrence et al., 1996). In a rat model of intra-abdominal sepsis, Dex 50 μg/kg 
intraperitoneal (i.p.) attenuated sepsis-induced kidney injury and apoptosis (Koca et al., 2013).
2.5.1.2 Dexmedetomidine and ischaemia-reperfusion injury
Dex attenuated myocardial infarcts (Ibacache et al., 2012) and protected against ischaemic brain 
(Kuhmonen et al., 1997; Jolkkonen et al., 1999; Maier et al., 1993), spinal cord (Bell et al., 2013), 
intestine (Kilic et al., 2012), liver (Tufek et al., 2013) and kidney (Gu et al., 2011b) injuries, 
as well as I/R-induced AKI-related lung injuries (Gu et al., 2011a) in animal models. It  was 
suggested that Dex  may establish  its protection against ischaemia through its anti-infl ammatory 
(Gu et al., 2011b) and/or antioxidative properties (Tufek et al., 2013), by the activation of cellular 
prosurvival kinases (Ibacache et al., 2012; Bell et al., 2013) and/or by decreasing the release of 
NA (Maier et al., 1993; Jolkkonen et al., 1999). A recent study of Tufek et al. 2013 showed that 
Dex 100 μg/kg i.p. reduces oxidative stress also in kidneys aft er hepatic I/R injury in rats.
In the study of Gu et al. (2011b), pre- and posttreatment with 25 ug/kg i.p. Dex attenuated 
I/R-induced AKI in mice. Pretreatment also increased the survival rates aft er nephrectomy. It 
was suggested that Dex protects kidneys through α2-AR-dependent decrease in the activity of the 
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infl ammatory high-mobility group protein B1-Toll-like receptor 4 (HMGB1-TLR4) circuit (Gu 
et al., 2011b). Previous clinical studies showed that α2-AR agonists can attenuate I/R-induced 
AKI (Kulka et al., 1996; Frumento et al., 2006).
Taoda et al. (2001) showed that Dex inhibits the release of NA in rat kidneys via activation 
of α2C-ARs. Activation of other α2-AR subtypes (2A and 2B) may also lead to reduction of 
NA release, at least in mouse kidneys (Taoda et al., 2001). During I/R injury, this may lead to 
decreased sympathetic activity and thus also enhance blood fl ow and protect the kidneys.
Renal sympathetic eff erent neurons are highly activated in human hypertension. Denervating 
the human kidney is an old therapeutic concept, but only new, minimally invasive, device-based 
approaches have enabled renal denervations with relatively small risks. Th is procedure reduces 
NA spillover from the kidneys to the circulation by 47%, decreases renin secretion and increases 
renal blood fl ow (Schlaich et al., 2012).
2.5.1.3 Haemodynamic effects of dexmedetomidine
Th e overall cardiovascular eff ects of Dex are known and can be derived from the pharmacological 
eff ects of α2-ARs (Lehtimaki et al., 2008). In clinical studies, a brief biphasic, dose-dependent, 
cardiovascular response was reported aft er the administration of Dex (Leino et al. 2009). A Dex 
bolus increases BP, which causes a refl ex drop in HR. It has been suggested that the stimulation 
of α2B receptors in vascular smooth muscle causes the increase in BP (Lehtimäki et al., 2008). 
Th is initial response lasts for 5--10 min, aft er which BP decreases, due to the inhibition of central 
sympathetic outfl ow. NA release is also decreased through presynaptic α2 receptors, which also 
decreases BP and HR (Afonso and Reis, 2012).
2.5.2  Fadolmidine
Fadolmidine (MPV-2426 hydrochloride, 3-(1H-imidazol-4ylmethyl)-indan-5ol hydrochloride) 
(Fado) is another α2-AR agonist. Pharmacokinetics and pharamacodynamics of fadolmidine 
have already been widely studied in previous preclinical studies. Fado has high affi  nity and full 
agonist effi  cacy for all three subtypes of human α2-AR (α2A, α2B and α2C). It also activates rodent 
α2D-ARs, as well as human α1A- and α1B-ARs. Weak α1-AR agonism has also been observed in 
rat vas deferens (Lehtimaki et al., 2008). Fado is a less lipophilic and more polar molecule than 
Dex, which makes it act more peripherally (Lehtimäki et al., 2008, Leino et al., 2009). Th is is also 
likely to explain why Dex might have some central eff ects (e.g. sedation) that fado does not have. 
Fado is known to have antinociceptive eff ects when administered intrathecally and it also lowers 
intraocular pressure. Its analgesic potency (eff ective dose 50 [ED50] = 0.73 μg) is greater than that 
of clonidine (ED50 = 6.4 μg) or Dex (ED50 = 2.2 μg) (Lehtimäki et al., 2008). Th e antinociceptive 
eff ects of Fado can be reversed by a selective α2-AR antagonist, atipamezole (Pertovaara and Wei, 
2000).
In the study of Leino et al. (2009), Fado decreased MAP at low doses (0.3 μg and 1 μg), 
whereas at higher doses (3 μg, 10 μg and 30 μg) there was an intitial peak in BP. In both cases, 
HR decreased simultaneously. At the 1-μg dose, which is already analgesic, Fado showed only 
minor haemodynamic eff ects (Leino et al., 2009). It is likely that this initial transient peak in BP 
was the result of peripheral vasoconstriction caused by Fado. However, it remains partly open 
whether this response was mediated only by α2-ARs or whether the α1-ARs also showed some 
eff ect (Lehtimaki et al., 2008).
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Aims of the study
3  Aims of the study
I/R (ischaemia-reperfusion) injury is a common cause of AKI (acute kidney injury). AKI oft en 
occurs in the context of MOF (multi organ failure) and sepsis and is associated with high mortality 
rates. Currently, there are no specifi c curative treatments available for I/R injury-induced AKI. 
Th e aim of the present study was to increase our understanding of the pathophysiological 
processes underlying acute ischaemic kidney injury and repair and to identify tentative drug 
targets for AKI. In particular, we investigated here whether three diff erent treatment strategies 
with tissue-protective and anti-infl ammatory properties, namely CR (caloric restriction), AMPK 
(adenosine monophosphate kinase) activation by AICAR (5-amino-4-imidazolecarboxamide 
riboside-1-β-D-ribofuranoside) and α2-AR (α2-adrenoceptor) activation by α2-AR agonists could 
ameliorate kidney I/R injury. Th e specifi c objectives of this thesis were the following:
1. To investigate whether preconditioning of the kidneys by CR could ameliorate kidney I/R 
injury and how the renoprotective eff ects of CR are mediated at the cellular level.
2. To investigate whether metabolic remodelling of the kidney with the AMPK activator 
AICAR ameliorates kidney I/R injury and whether the salutary eff ects of AICAR are 
mediated through antioxidative and anti-infl ammatory mechanisms.
3. To explore the mechanisms and time course behind the renoprotective eff ects of the 
centrally acting α2-AR agonist Dex and whether metabolic reprogramming is involved.
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4 Materials and methods
4.1  Experimental animals and ethical issues (I-III)
Th e investigation conforms to the Guide For the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Th e protocols 
were approved by the Provincial State Offi  ce of Southern Finland/ National Animal Experiment 
Board (approval number STH059A). Th e rats were kept under a 12-h light/12-h dark cycle. In 
Study I, the rats in the CR groups had free access to water, but were given access to only 70% of 
the food their littermates consumed daily. In all other studies, all rats had free access to food and 
water. Th e rats were purchased from Charles River Laboratories (Research Models and Services, 
Sulzfeld, Germany). Wistar (WT) rats were used in the fi rst study and Sprague Dawley (SD) rats 
in the second and third studies.
4.2  Study design (I-III)
4.2.1  Murine model of ischaemia-reperfusion injury (I-III)
An established model of renal I/R injury was used in all three studies (Kennedy and Erlich, 
2008). Th e rats were anaesthetized with isofl urane and a single dose of buprenorphine (0.1 
mg/kg intramuscular [i.m.], given 5 min before surgery) was used as an analgesic. Bilateral 
renal ischaemia was induced by clamping the renal pedicles for 40 min with microvascular 
clamps. Control animals were subjected to sham operations without renal pedicle clamping. 
Th e rats were hydrated with warm saline during the operation and the body temperature was 
maintained constantly at 37 °C. Th e wounds were sutured aft er removing the clips. Th e rats 
were anaesthetized with isofl urane 24 h aft er the operation, and blood samples were collected 
from the inferior vena cava for biochemical measurements. Th e kidneys were excised, washed 
with ice-cold saline, blotted dry and weighed. Th e left  kidney was used for Western blotting, 
polymerase chain reaction (PCR) and histological examinations. Tissue samples for histology 
were fi xed in 10% formaline and processed to paraffi  n with routine methodology. Samples for 
immunohistochemistry were snap-frozen in -38 °C isopentane. For protein and gene expression 
studies, renal samples were snap-frozen in liquid nitrogen. Th e samples were stored at -80 °C. 
For more details see the original publications.
4.2.2  Design of Study I
Twentyeight 6--7-week-old male WT rats were divided into three groups: 1) Sham-operated 
controls (n = 9), 2) I/R group (n = 10) and 3) I/R group + CR initiated 2 weeks before the I/R 
operation (n = 9). CR was calculated from the food intake of pair-fed WT controls fed ad libitum. 
Th e CR rats were only given access to 70% of the food their littermates consumed daily, whereas 
the control rats had free access to chow (Harlan Laboratories, Boxmeer, Th e Netherlands) 
and drinking water. To further investigate the molecular mechanisms of CR, we conducted an 
additional study with the following four groups (n = 6 in each group): 1) I/R group, 2) I/R group 
+ CR, 3) I/R group + CR treated with the autophagy inhibitor 3-methyladenine (3-MA) (30 mg/
kg i.v. given  1 h before the operation) and 4) I/R group + CR treated with the SIRT1 inhibitor 
sirtinol (1 mg/kg i.v. given  1 h before the operation). Th e drug dosages of 3-MA and sirtinol 





4.2.3  Design of Study II
6--7-week-old SD rats were divided into fi ve groups: 1) Sham-operated controls treated with 
sodium chloride (NaCl) 0.9% 5 ml/kg i.v (n = 17), 2) I/R group treated with NaCl 0.9% 5 ml/kg 
i.v (n = 19), 3) I/R group treated with AICAR , Bepharm Ltd, Shanghai, China) 50 mg/kg i.v (n 
= 8), 4) I/R group treated with AICAR 160 mg/kg (n = 9) and 5) I/R group treated with AICAR 
500 mg/kg i.v (n = 8). An additional study with two groups (n = 6), the sham group and sham 
treated with AICAR 500 mg/kg i.v., was performed to further evaluate the eff ects of AICAR on 
the serum biochemical markers. Th e AICAR was suspended in NaCl 0.9% and injected i.v. 60 
min before the operation.
4.2.4  Design of Study III
In Study III, four diff erent protocols were performed.
In the fi rst protocol, the eff ects of dexmedetomidine preconditioning on kidney I/R injury were 
evaluated, using  6--7-week-old SD rats  divided into four groups (n = 8--11 per group): 1. Sham-
operated group, 2. I/R group (40 min bilateral ischaemia followed by 24 h of reperfusion, 3. I/R 
group + Dex (1 μg/kg i.v. given 60 min before the surgery) and 4. I/R group + Dex (10 μg/kg 
i.v.). Th e Dex was given as an i.v. bolus 60 min before the surgery. In additional experiments, the 
eff ects of Dex infusio ns (0.1  μg kg-1 min-1  or 0.3  μg kg-1 min-1 started 60 min before surgery and 
continued until the 30-min reperfusion period) (n = 10 in both groups) on kidney I/R injury 
were also examined. Blood samples were taken during the follow-up period for pharmacokinetic 
(PK) analyses.
To explore whether Dex establishes its renoprotective eff ects through inhibition of 
necroptosis (a form of programmed necrosis), we also conducted an additional study with the 
following four groups (n =10 in each group): 1) I/R group, 2) I/R group + Dex (10 μg/kg i.v 60 
min before ischaemia), 3) I/R group + the necroptosis inhibitor necrostatin-1 (Nec-1) (1.65 mg/
kg i.p. given 15 min before ischaemia) and 4) I/R group + Dex + Nec-1.
In the second protocol, the eff ects of Dex postconditioning on kidney I/R injury were 
evaluated. Th e rats were again divided into four groups (this time n = 5--10 per group): 1. Sham-
operated group, 2. I/R group (40-min bilateral ischaemia followed by 24 h of reperfusion, 3. I/R 
group + Dex (1 μg/kg i.v. given immediately aft er the 40-min ischaemic period) and 4. I/R group 
+ Dex (10 μg/kg i.v.).  
In the third protocol, the eff ects of pre- and postconditioning with the peripheral α2-AR 
agonist fadolmidine on kidney I/R injury were examined, as outlined in protocols 1 and 2. Fado 
preconditioning was given as an i.v. bolus 60 min before the surgery at a dosage of 1 μg/kg or 10 
ug/kg (n = 7--18 per group). Fado postconditioning (n = 5--10 per group) was given as an i.v. 
bolus (1 and 10 μg/kg) given immediately aft er the 40-min ischaemic period.
In the fourth protocol, the haemodynamic eff ects of Dex and Fado, 1 μg/kg and 10 μg/kg 
preconditioning bolus groups and 0.1 μg kg-1 min-1 and 0.3  μg kg-1 min-1 infusion groups (n = 5 
or 6 per group) on kidney I/R injury were evaluated.
4.3  Blood pressure and heart rate measurement (III)
Th e haemodynamic eff ects (i.e. HR and BP) of Dex and Fado preconditioning on kidney I/R 
injury were continuously recorded,  using an intra-arterial catheter inserted into the carotid 
artery and a Powerlab system (ADInstruments GmbH, Spechbach, Germany).
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4.4  Biochemical determinations (I-III)
Creatinine, urea and electrolytes from serum samples as well as serum lipids and liver enzymes 
were measured by routine laboratory techniques (ADVIA 1650 Chemistry System, Siemens 
Healthcare Diagnostics Inc., Deerfi eld, IL, USA and Konelab 30i, Th ermoFisher Scientifi c, 
Vantaa, Finland).
For the analysis of protein carbonyls (II), renal samples were analysed with an OxiSelect(TM) 
Protein Carbonyl enzyme-linked immunosorbent assay (ELISA) Kit (Cell Biolabs, Inc., San 
Diego, CA, USA), according to the manufacturer`s instructions.
Dex plasma concentrations (III) were determined in a separate pharmacokinetic (PK) study, 
in which blood samples were taken at 0.25, 0.5, 2 and 3 h from the tail vein of conscious rats. 
Th e Dex concentrations were determined by a validated liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) method. Th e estimate for plasma concentration at 1 h was performed, 
using nonlinear fi t in GraphPad Prism soft ware (v6.02).
Drug concentrations aft er the various Dex infusion rates were measured from plasma 
samples taken just before the reperfusion phase (100 min aft er beginning of infusion) (n = 7 
in each infusion group and n = 2 or 3 for each time point aft er the i.v. bolus). For the bolus and 
infusion PK studies, the lower limits of quantifi cation were 0.0200 and 0.100 ng/ml for Dex.
4.5  Kidney histology (I-III)
For histological examination, 4-μm-thick paraffi  n sections were cut and stained with 
haematoxylin-eosin (n = 8--19 per group). Th e renal samples were visually examined by a 
pathologist with a Leica DMR microscope (Leica Microsystems AG, Heerbrugg, Switzerland) 
and morphological changes from the  entire cross-sectional area of the cortex and medulla were 
assessed according to the ATN--scoring system adopted from Dragun et al. (2001) (magnifi cation 
x 200, ≥ 20 fi elds per kidney section quantifi ed using the ATN-scoring system). Evaluation of 
histopathological changes included loss of the tubular brush border, tubular dilatation, cast 
formation and cell lysis. Tissue damage was quantifi ed in a blinded manner and scored according 
to the percentage of damaged tubules in the sample: 0, no damage; 1, less than 25% damage; 2, 
25--50% damage; 3, 50--75% damage; and 4, more than 75% damage.
4.6  Immunohistochemistry (I-III)
For immunohistochemistry, frozen kidneys were processed, processed with primary and 
secondary antibodies and semiquantitative scoring of infl ammatory cells and kidney 
nitrotyrosine expression was performed (n = 8--19), as described in detail elsewhere (Helkamaa 
et al., 2003). Th e relative amount of antibody-positive signalling in the cortical and medullary 
areas per sample was determined with computerized densitometry (Leica IM500 and Leica 
QWIN soft ware, Leica Microsystems ). See the original publications for details.
4.7  Western blotting (I-III)
Proteins from kidney samples were isolated with lysis buff er and complete protease inhibitors 
(Roche Diagnostics, Neuilly-Sur-Seine, France). Tissue samples were homogenized, using 
a Bertin Precellys 24 homogenizer (Bertin Technologies, Aix en Provence, France). Nuclear 
proteins for assessment of SIRT1 were extracted with Microcon´s YM-10 fi lters and Centrifugal 
Filter Units (Millipore, Bedford, MA, USA), according to the instructions of the manufacturer. 
Materials and methods
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Th e protocol was fi rst described by Schreiber et al., (1989). Th e samples were electrophoretically 
separated and proteins were transferred to a polyvinylidene fl uoride (PVDF) membrane 
(Immobilon-P®, Millipore). Th e membranes were probed with the primary and secondary 
antibodies. See the original publications for the details of the protocol. Th e relative protein 
expressions in separate samples from the membranes were quantifi ed with a fl uorescent image 
analyser (FUJIFILM Corp, Tokyo, Japan).
For the detection of AMPK, AMPK-P, eNOS, eNOS-P and PGC-1α,  the PVDF membrane 
was blocked in Odyssey blocking buff er (LI-COR Biosciences, Lincoln, NE, USA) and IRDye 
680LT goat antirabbit (1/7500, LI-COR Biosciences) and IRDye 800CW goat antimouse (1/10 
000, LI-COR Biosciences) secondary antibodies were used. Th e protein expressions were 
detected by direct infrared fl uorescence on the Odyssey CLx infrared imaging system (LI-COR 
Ltd, Cambridge, UK), according to the instructions of the manufacturer.
4.8  Quantitative RT-PCR (I-II)
Quantitative (real-time) reverse-transcription polymerase chain reaction (qRT-PCR) 
was performed, using the LightCycler instrument (Roche Diagnostics) for detection of 
monocyte chemotactic protein-1 (MCP-1), NADPH oxidase 1 (Nox1), mitochondrial 
superoxide dismutase (MnSOD), catalase and ribosomal 18S mRNA, as described elsewhere 
(Louhelainen et al., 2007). Th e following primers were used: MCP-1 sequence (5´-3´) forward 
GCAGGTCTCTGTCAGGCTTCT, reverse GGCTGAGACAGCACGTGGAT; Nox1-2 forward 
GGAGTTGCAGGAGTCCTCATTTT, reverse TTCTGCCGGGAGCGATAA; MnSOD 
forward TTAACGCGCAGATCATGCA, reverse CCTCGGTGACGTTCAGATTGT; catalase 
forward TCAGCGACCGAGGGAT, reverse GGGCTGGGCTCAATGC; and 18s forward 
ACATCCAAGGAAGGCAGCAG, reverse TTTTCGTCACTACCTCCCCG. See the original 
publications for the details of the protocol.
4.9  Microarray (III)
Kidney samples from the I/R injury group with and without Dex preconditioning (n = 3 in both 
groups) were preserved in liquid nitrogen. Total RNA was isolated with TRIzol Reagent (Gibco, 
Invitrogen) and purified with the RNeasy mini kit (Qiagen, Valencia, CA, USA), according to 
the manufacturers’ instructions. Th e concentration and integrity of total RNA were analysed 
with a spectrophotometer and 2100 Bionanalyser (Agilent Technologies, Santa Clara, CA, 
USA). Further sample processing and hybridization to Sureprint G3 Rat GE 8x60K microrrays (Agilent 
Technologies), representing over 30 000 rat transcripts, was performed by the Biomedicum Functional 
Genomics Unit (www.helsinki.fi /fugu/). Th e data were normalized to the median with the Robust Multi-
Array Analysis (RMA) reprocessing algorithm and analysed with Genespring 11 soft ware (Agilent 
Technologies). Diff erentially expressed probe sets were selected, based on fi ltering by parametric 
statistical analysis, not assuming equal variances (Welch-type t test) with P < 0.05 as a threshold 
for signifi cance, followed by fi ltering for fold change (±1.2-fold) between the groups compared. 
Th e functional annotation describing the categorical data for gene ontology and pathway 
information for the lists of genes were performed with DAVID (Database for Annotation, 
Visualization and Integrated Discovery, 2008) (Dennis et al., 2003). Th e data were also analysed 
through the use of Ingenuity Pathway Analysis (IPA) (Ingenuity® Systems, www.ingenuity.com).
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4.10  Statistical analysis (I-III)
Th e data are presented as the mean ± standard error of the mean (SEM). Statistically 
signifi cant diff erences in mean values were tested by analysis of variance (ANOVA) and the 
Bonferroni’s post-hoc test, or by the Student’s T-test, when appropriate. Th e diff erences were 




5.1  Renal function and morphology (I-III)
5.1.1  Kidney function 
Acute kidney I/R injury was associated with a 7.1-8.5-fold increase in S-creatinine concentration 
and a 7.0-8.5-fold increase in S-urea concentration as compared to sham-operated controls.
A 2-week CR period (70% ad libitum) before the I/R injury prevented AKI-induced kidney 
dysfunction with the maximal 17% decrease in S-creatinine concentration (Figure 1A). CR did 
not aff ect the S-urea concentration (Figure 1B).
 
Figure 1. Eff ects of CR on serum creatinine (Panel A) and serum urea concentrations (Panel B) in rats 
with renal ischaemia-reperfusion (RIR) injury. Sham denotes sham-operated rats and RIR, rats with 
renal I/R injury. RIR CR denotes rats with I/R injury treated with CR initiated 2 weeks before the I/R 
operation. Means ± SEM are given, n = 9 or 10 in each group. *P < 0.05 vs. Sham; #P < 0.05 vs RIR.
AMPK activator AICAR 500 mg/kg i.v. decreased the S-creatinine and S-urea concentrations 
by 35% and 25%, respectively, whereas the lower AICAR doses did not signifi cantly infl uence the 




Figure 2. Eff ects of AICAR on serum creatinine (Panel A) and serum urea concentrations (Panel B) 
in rats with renal ischaemia-reperfusion injury. RIR+AICAR50 denotes rats with I/R injury treated 
with AICAR at  a dose of 50 mg/kg i.v.; RIR+AICAR160, rats with I/R injury treated with AICAR at 
160 mg/kg i.v.; RIR+AICAR500, rats with I/R injury treated with AICAR at  500 mg/kg i.v.  AICAR 
denotes 5-amino-4-imidazolecarboxamide riboside-1-β-D-ribofuranoside. For other abbreviations 
see Figure legend 1. Means ± SEM are given, n = 8--19 in each group. *P < 0.05 vs. Sham; #P < 0.05 vs 
RIR; ¤ P < 0.05 vs RIR+AICAR50.
Preconditioning with an α2-adrenoceptor agonist Dex-10 μg/kg bolus decreased the 
S-creatinine concentration by 30% and S-urea concentration by 23%, while the smaller dose (1 
μg/kg) did not infl uence kidney function (Figure 3). Continuous Dex infusions (0.1 μg kg-1 min-1 
or 0.3  μg kg-1 min-1) did  not  aff ect  the S-creatinine or S-urea levels.
 
 
Figure 3. Eff ects of Dex preconditioning on serum creatinine (Panel A) and serum urea concentrations 
(Panel B) in rats with renal ischaemia-reperfusion injury.  Dex denotes rats with I/R injury treated 
with dexmedetomidine. For other abbreviations see Figure legend 1. Means ± SEM are given, n = 
7--11 in each group. *P < 0.05 vs. Sham; #P < 0.05 vs RIR. ¤P < 0.05 vs Dex 1-μg/kg bolus.
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A Dex 1-μg/kg or 10-μg/kg i.v. bolus administrated 40 min aft er the ischaemic period 
(postconditioning) did not aff ect the S-creatinine or S-urea levels.
Fado preconditioning with a 10-μg/kg bolus decreased S-creatinine 19% and S-urea by 17%, 
compared with the I/R injury group; however, the diff erences were not statistically signifi cant. A 
smaller (1-μg/kg) Fado bolus did not aff ect the S-creatinine or S-urea. A Fado 1-μg/kg or 10-μg/
kg bolus administered 40 min aft er the ischaemic period (postconditioning) did not aff ect the 
S-creatinine or S-urea levels.
5.1.2  Kidney morphology
Histopathological analysis of the kidneys harvested 24 h aft er I/R showed marked injury of 
the renal parenchyma comprising vast necrosis of the tubuloepithelial cells, tubular dilatation 
and cast formation. A 2-week CR period, AICAR 500 mg/kg i.v. and Dex preconditioning all 
ameliorated I/R injury-induced ATN. Dex postconditioning or Fado (preconditioning or 
postconditioning) did not aff ect I/R injury-induced ATN. See the original publications.
5.2  Oxidative/nitrosative stress (I-II)
Acute kidney I/R injury was associated with a 2.2-12.5-fold increase in renal nitrotyrosine 
expression as compared to sham-operated controls. A 2-week CR preconditioning period 
normalized the amount of nitrotyrosine and also AICAR 160 mg/kg signifi cantly ameliorated 
renal nitrosative stress (Figure 4). I/R AKI or AICAR treatment did not aff ect the expression of 
Nox1 or protein carbonyl levels in the kidneys. Th e expression of catalase was lower in I/R injury 
groups, as compared with the sham-operated controls. AICAR did not aff ect this decrease. See 
the original publications for details.
5.3  Inflammation (I-III)
5.3.1  Inflammatory 
  mediators
I/R AKI was associated with a 4.0-23-
fold increase in the number of ED1-
positive infl ammatory cells in the 
kidney. Pre-conditioning with Dex 
10 μg/kg ameliorated the I/R injury-
induced monocyte/macrophage 
infi ltration (Figure 5). A 2-week CR 
period did not aff ect the ED1 cell count. 
In Study II the number of renal ED1-
positive cells in the sham-operated 
group and in the groups with the two 
highest AICAR doses was statistically 
at the same level. See the original 
publications.
 
Figure 4. Eff ects of AICAR on nitrosative stress 
measured as kidney nitrotyrosine expression in rats with 
renal ischaemia-reperfusion injury. Means ± SEM are 
given, n = 8--19 in each group. *P < 0.05 vs. Sham; #P < 
0.05 vs RIR. For abbreviations see Figure legend 1.
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Figure 5. Eff ects of Dex 10 μg/kg 
preconditioning on monocyte/macrophage 
infi ltration in rats with renal ischaemia-
reperfusion injury. Means ± SEM are given, n 
= 10 or 11 in each group. *P < 0.05 vs. Sham; 
#P < 0.05 vs RIR. For abbreviations see Figure 
legend 1.
5.3.2 Inflammatory pathways 
 and chemokines
 I/R AKI was associated with a 1.1-1.6-
fold increase in expression of TLR-4 in rat 
kidneys. CR and Dex showed no notable 
eff ects on TLR-4 expression.
In Study I, AKI was associated with a 
59-fold increase in MCP-1 [also known as Chemokine (C-C motif) ligand 2, (CCL2)] mRNA 
levels (p < 0.05). CR partially counteracted this increase, so that in the CR group kidney MCP-1 
mRNA expression showed only a 9.3-fold increase, compared with the sham group (Figure 6A). 
Pharmacological inhibition of autophagy by 3-MA showed a statistically insignifi cant increase in 





Figure 6. Eff ects of CR on kidney MCP-1 mRNA expression in rats with renal ischaemia- reperfusion 
injury. Th e mRNA levels measured by qRT-PCR are given in Panels A and B. 3-MA denotes 
3-methyladenine. For other abbreviations see Figure legend 1. Means ± SEM are given, n = 6--10 in 
each group. *P < 0.05 vs. Sham. 
5.4  Pathways of metabolism and survival (I-III)
5.4.1  SIRT1
I/R AKI was associated with a 2.6-26 -fold increase in kidney SIRT1 expression, compared with 
the sham-operated controls. CR furthermore increased the I/R-induced SIRT1 expression by 
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4.6-fold, compared with the sham group (p < 0.001). Th e I/R injury-induced increase in kidney 
SIRT1 expression was prevented with AICAR treatment in a dose-dependent manner. Dex did 
not signifi cantly aff ect kidney SIRT1 expression. See the original publications.
5.4.2  AMPK
Kidneys harvested 24 hours aft er I/R injury showed a 40-50% decrease in the ratio of 
phosphorylated/total AMPK expression as compared to sham-operated rats. Th e total expression 
of AMPK in the kidney remained unaltered in Studies I and II and was increased increased 150% 
in Study III. CR did not noticeably aff ect the AMPK expression or AMPK-P/AMPK ratio aft er 
I/R, whereas AMPK activator AICAR 500 mg/kg signifi cantly increased the phosphorylation 
level of AMPK in the kidneys. Dex did not signifi cantly aff ect the AMPK. See the original 
publications.
5.4.3  eNOS
In Study I acute kidney I/R injury was associated with a 77% decrease, and in Study II a 19% 
decrease, in kidney eNOS expression as compared to sham-operated controls. CR partially, 
statistically non-signifi cantly, increased kidney eNOS expression (1.9-fold increase in eNOS 
expression compared to I/R injury group), whereas kidney eNOS expression in CR group did 
not diff er from that of sham-operated controls (p=0.61). AICAR 160mg/kg further decreased 
expression of eNOS as compared to I//R injury group (p<0.05). In Study III acute kidney I/R 
injury was associated with a 1.9-fold increase in total expression of eNOS in rats kidneys. 
I/R injury did not have any eff ect on eNOS-P expression level (study III). Dex treatment was 
associated to a 1.8-fold increase in the expression of eNOS-P as compared to sham group 
(p<0.05), but didn´t change amount of total eNOS. See the original publications.
5.4.4  PGC-1α
In Study I, I/R induced AKI decreased expression of PGC-1α was by 44%, compared the sham-
operated control group. CR counteracted this decrease by increasing PGC-1α expression by 45%, 
compared with the I/R AKI group. Expression of kidney PGC-1α (p = 0.68) in the CR group did 
not diff er from that in the sham group. See the original publications.
5.4.5  p38 MAPK
In study III, kidney I/R injury increased the p38 MAPK expression by 1.6-fold and the 
phosphorylated form of p38 MAPK by 1.4-fold, compared with the sham-operated animals. Dex 
further increased the expression of both forms of p38 MAPK. See the original publications.
5.4.6  Autophagy
I/R AKI decreased the autophagy marker light chain 3B (LC-3B) 14 kDa/16 kDa ratio by only 
0.4-fold in the kidneys, compared with the sham group. CR prevented this decrease in the ratio, 
indicating that it boosted autophagy (Figure 7A). Th e same eff ect was also seen with the active 
14-kDa form alone. AKI decreased the expression level of the LC-3B 14-kDa form by only 0.3-
fold, compared with the sham-operated animals and CR normalized it (Figure 7B).
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Figure 7. Eff ects of CR on kidney LC-3B 14 kDa/16 kDa ratio (Panel A) and LC-3B 14 kDa expression 
(Panel B) in rats with renal ischaemia-reperfusion injury. Th e LC-3B 14 kDa/16 kDa ratio and LC-3B 
14-kDa expression  were measured by Western blotting  (20 μg total protein of the whole-cell lysate 
per lane). Means ± SEM are given, n = 6 or 7 in each group. *P < 0.05 vs. Sham; #P < 0.05 vs RIR. For 
abbreviations see Figure legend 1.
Also Dex 10μg/kg i.v. preconditioning bolus attenuated the kidney I/R injury-induced 
decrease in the LC-3B 14 kDa/16 kDa ratio, as well as in the LC-3B 14-kDa expression level. See 
the original publications for more details.
5.4.7  I/R and dexmedetomidine –induced changes in gene expression
Dex treatment altered the expression of 306 genes, compared with the RIR group; 245 of these 
genes were downregulated with Dex treatment and 61 genes were upregulated. Th ere were 
17 enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways among all the 
regulated genes, of which ECM receptor interaction, hypertrophic cardiomyopathy (HCM), 
TGF-β signalling, dilated cardiomyopathy, focal adhesion, regulation of the actin cytoskeleton, 
chemokine signalling and pathways in cancer  development were most significantly enriched 
(Table 1).
Ingenuity analysis revealed inhibition of RAC and nuclear factor erythroid 2-related factor 
(NRF2) pathways, whereas the ‘aryl hydrocarbon receptor’ (AHR) pathway was activated. Dex 
decreased the expression of Rab27b, Rasa2 and cell division control protein 42 homologue (CDC42)-
binding protein kinase alpha isoform B, which are all associated with RAC signalling.  Expression of 
two RAB GTPase (also members of the RAS superfamily)-associated genes, RAB GTPase-activating 
protein 1 (Rabgap1) and RAB GTPase-binding eff ector protein 1 (Rabep1), also decreased with Dex 
treatment. Moreover, Ingenuity analysis also revealed that Dex treatment decreased the expression 




































































































































































































































































































































































































































































































































































































5.5  Haemodynamic and pharmacokinetic measurements (III)
5.5.1  Haemodynamic effects
Th e mean arterial pressure (MAP) baseline before administration of dexmedetomidine or 
fadolmidine averaged 107.1  ± 11.3 mmHg and heart rates 405  ± 35 beats per minute (BPM).
Th ere were no diff erences between the groups (ANOVA P = 0.09 and P = 0.32, respectively).
Dex decreased MAP more than did Fado (Figure 8). Th e percentage change in MAP was 
dose-dependent with both drugs in the bolus groups (Figure 8A). Dex infusions (0.1 μg kg-1 
min-1 and 0.3 μg kg-1 min-1) decreased MAP to a similar extent, compared with the higher Dex 
bolus, whereas neither of the Fado infusions infl uenced MAP (Figure 8B). Th e percentage change 
in MAP 0--50 min aft er administration of the drugs with the Dex 10-μg/kg bolus diff ered from 
that in all other bolus groups (Figure 8A).
Th e higher bolus dose of Fado also had a slight hypotensive eff ect (Figure 8A). Th e largest 
percentage change in MAP with the bolus groups was caused by the Dex 10-μg/kg bolus 8 min 
aft er administration of the drugs and with the infusions in the Dex 0.3- μg kg-1 min-1 group aft er 
18 min.
 
Figure 8. Eff ects of Dex and Fado on MAP before the ischaemic period. Percentage changes of MAP 
from the baseline, represented  by the AUC values, during 0--50-min time period aft er administration 
of the drugs for the bolus groups, are given in Panel A and for the infusion groups in Panel B. n = 5 
or 6 in each group. *P < 0.05 vs. NaCl 0.9%; #P < 0.05 vs Dex 1-μg/kg bolus; ¤P < 0.05 vs Dex 10-μg/
kg bolus; SP < 0.05 vs Dex 0.1- μg kg-1 min-1 infusion; α P < 0.05 vs Dex 0.3- μg kg-1 min-1 infusion. 
AUC = area under the curve, Dex = dexmedetomidine, MAP = mean arterial blood pressure, min = 
minutes, NaCl 0.9% = sodium chloride 0.9%. For other abbreviations see Figure legend 1.
5.5.2  Dexmedetomidine plasma concentrations
Th e plasma Dex concentrations 15 min, 30 min, 120 min and 180 min aft er the 10-μg/kg 
bolus administration were 2.8 ng/ml, 0.80 ng/ml, 0.28 ng/ml and 0.16 ng/ml, respectively. 
Calculated from the measured time points, the plasma Dex concentration at time point 60 min 
(corresponding to the time point when the ischaemic period  was initiated) and time point 40 
min (corresponding to the time point when reperfusion was initiated) were 0.38 ng/ml and 
0.33 ng/ml, respectively. Th e plasma Dex concentrations at time point 90 min aft er continuous 
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infusion with infusion rates of 0.1 μg kg-1 min-1 and 0.3 μg kg-1 min-1 were 0.58 ng/ml and 1.3 ng/
ml, respectively.
5.6  Serum biochemistry (I-III)
Acute kidney I/R injury was associated with 55-98%, 26%, and 340-530% increases in the 
serum concentrations of alanine aminotransferase, alkaline phosphatase, and aspartate 
aminotransferase, respectively, as compared to sham-operated controls, indicating AKI-induced 
hepatic injury (Tables 2-4). Acute kidney injury also markedly increased the serum levels 
of SGGT (serum gamma-glutamyl transferase, Studies I-III) and SGLDH (serum glutamate 
dehydrogenase, Study II). Two weeks pretreatment with CR before the I/R injury decreased serum 
alanine aminotransferase, aspartate aminotransferase and SGTT levels (Table 2). Th e highest 
dose of AICAR decreased serum aspartate aminotransferase level but did not restore other 
markers of I/R-injury-induced hepatic damage/dysfunction (Table 3). Also pretreatment with 
dex before the I/R injury decreased serum alanine aminotransferase, aspartate aminotransferase 
and SGTT levels (Table 4).
AICAR treatment alone without I/R injury increased the serum concentrations of ALAT 
by1.3-fold and ASAT by 1.4-fold, compared with the sham-operated controls. Other biochemical 
markers studied were not markedly infl uenced by AICAR treatment alone (See study II 
Supporting Information Table S1).
Statistically signifi cant results are shown in tables 2-4. See the original publications for other 
biochemical markers measured.
Table 2. Eff ects of two weeks CR on serum biochemistry in rats with kidney I/R injury.  Sham denotes 
sham-operated rats; RIR, rats with renal I/R injury; CR, rats with I/R injury treated prior with two 
weeks caloric restriction (70% ad libitum). Means ± SEM are given, n= 9-10 in each group. *P<0.05 vs 









s-ALAT (U/l) 45,8±3,3 71,0±5,9* 63,3±13,5# 0,0004
s-ASAT (U/l) 106±6,1 667±41,6* 612±195,8*# <0.0001
s-GGT (U/l)                   0,0±0,0 27,0±3,9* 16,93±5,2*# <0.0001
s-K (mmol/l) 4,3±0,1 6,4±0,4* 6,9±0,5* <0.0001
s-Pi (mmol/l) 3,1±0,1 4,3±0,2* 3,4±0,2# <0.0001
s-Trigly (mmol/l) 0,8±0,1 1,3±0,1* 0,83±0,1# 0,0007
s-Gluc (mmol/l) 7,1±0,3 6,1±0,2 7,6±0,5# 0,0029
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Table 3. Eff ects of AICAR treatment on serum biochemistry in rats with kidney I/R injury.  Sham 
denotes sham-operated rats; RIR, rats with renal I/R injury; RIR+AICAR50, rats with I/R injury 
treated with AICAR at the dose 50 mg/kg i.v.; RIR+AICAR160, rats with I/R injury treated with 
AICAR at the dose 160 mg/kg i.v.; RIR+AICAR500, rats with I/R injury treated with AICAR at the 
















s-ALAT (U/l) 39.3±2.8 77.7±4.2* 67±7.1* 59±4.0* 62±6.2* 0.2413
s-ASAT (U/l) 120.4±5.9 612.5±42.1* 648±96.3* 505±52.1* 374±49.2*# <0.0001
s-GGT (U/l)             0.0±0 27.3±2.6* 26.1±6.0* 19.2±2.8* 13.2±2.5*# <0.0001
s-GLDH (U/l) 10.0±0.8 198.8±19.8* 195±28.0* 201±24.4* 129±31.7* <0.0001
s-K (mmol/l) 4.7±0.1 6.9±0.3* 6.4±0.3* 6.1±0.2* 5.6±0.3# <0.0001
s-Pi (mmol/l) 2.9±0.1 4.7±0.3* 4.3±0.3* 4.2±0.3* 3.7±0.3 <0.0001
Table 4. Eff ects of dexmedetomidine treatment on serum biochemistry in rats with kidney I/R injury. 
Sham denotes sham-operated rats; RIR, rats with renal I/R injury; dex, rats with I/R injury treated 
with dexmedetomidine at dose 10ug/kg i.v.. Means ± SEM are given, n= 6-11 in each group. *P<0.05 









s-ALAT (U/l) 46,2±3,0 85,2±5,0* 56,6±3,2# <0.0001
s-ASAT (U/l) 129±7,2 571±44,4* 316,1±39,5*# <0.0001
s-GGT (U/l)          <1,0 29,3±3,6* 16,1±3,6*# <0.0001
s-K (mmol/l) 4,6±0,1 6,6±0,3* 5,0±0,1# <0.0001
s-Cl (mmol/l) 97,3±0,9 89,0±1,8* 98,2±1,6# 0,0005
s-Pi (mmol/l) 2,9±0,1 4,9±0,3* 3,6±0,3# <0.0001
5.7  Summary of the main findings (I-III)
A 2-week CR, AICAR and pretreatment with Dex all ameliorated kidney function and attenuated 
acute tubular necrosis aft er I/R induced AKI. Infl ammation and oxidative stress in kidneys 
were also diminished. Treatment with AICAR increased amount of phosphorylated AMPK in 
kidneys. CR increased kidney SIRT1 expression and maintained also kidney autophagy levels. 
Also Dex preconditioning maintaned levels of autophagy and increased expression of p38 MAPK 
in kidneys. CR, AICAR and Dex all attenuated kidney I/R injury- associated hepatic injury. See 
Table 5 for more details.
Results
41
Table 5. Eff ects of CR, AICAR and Dex treatments on kidneys in rats with kidney I/R injury.  CR 
denotes rats with I/R injury treated before injury with 2-week caloric restriction; AICAR, rats 
treated with AICAR; Dex, rats treated with dexmedetomidine; ATN, acute tubular necrosis; NA (not 
available), parameter was not examined in the particular study;  = increased;  = decreased; 
= no change, compared with the I/R injury group. Th e degree of change is based on the author´s 
interpretation.
Variable CR AICAR Dex
Kidney function ↑ ↑ ↑
ATN ↓ ↓ ↓
Infl ammation ↓ ↓↓ ↓↓
Oxidative stress                                     ↓ ↓ NA
Phosphorylation  ratio of AMPK ↑/↓ ↑ ↑/↓
SIRT1 ↑ ↓ ↑/↓
eNOS ↑ ↓ ↑/↓
eNOS-P NA NA ↑
PGC-1a ↑ NA NA
Autophagy ↑ NA ↑
p38-P NA NA ↑




I/R-induced AKI is a common problem among hospitalized patients, mortality rates are high 
and currently there is no specifi c medication in use (Waikar et al., 2008). Th e pathophysiology 
of I/R-induced AKI is complex and still incompletely understood (Bonventre and Yang, 2011). 
Th is thesis project was undertaken to fi nd new ways to alleviate AKI and shed light on its 
pathophysiology.
6.1  Methodological aspects
6.1.1  Experimental animal model
An established murine (rat) model, which was developed to study I/R-induced AKI and has 
many similarities to human I/R-induced AKI, was used in all experiments (Kennedy and Erlich, 
2008). In this animal model, the surgical operations can be performed relatively quickly and the 
duration of ischaemia and collection of samples can also be performed at exact time points. Th e 
model is widely used and there are already abundant background data available (e.g. changes 
seen in clinical chemistry and kidney histology) from it. In contrast to mice, rats are larger and 
thus the surgical procedure is easier. With rats, there are also many well-established strains 
available.
Th ere are some structural, haemodynamic and molecular diff erences among rodent, larger 
animal and human kidneys (Kennedy and Erlich, 2008). In our RIR model, bilateral renal 
ischaemia was induced by clamping the renal arteries for 40 min with microvascular clamps. Pig 
kidneys may be more like human kidneys than those of mice, rats and dogs. However, practical 
reasons such as availability, ethical issues and the fact that pigs are not as amenable to genetic 
modifi cation as rodents limit the use of this model.
It should also be noted that humans rarely experience the isolated ischaemic events studied 
here, and very oft en they also have other clinical conditions, such as hypertension, diabetes, 
congestive heart failure or drug abuse, which also damage the kidneys. Th is also warrants further 
studies with ‘unhealthy’ animals, e.g. diabetic Goto-Kakizaki (GK) and hypertensive double-
transgenic (dTGR) rats.
Th e prognosis aft er 40 min of total ischaemia and a slight increase in the S-creatinine value 
(seen with many hospitalized patients) varies greatly. In ICUs, over 50% of patients undergoing 
renal replacement therapy die (Waikar et al., 2008). In mice aft er unilateral nephrectomy and 
unilateral 37-min ischaemia, the mortality rates exceeded 90% in 4 days (Mitchell et al. 2010). 
Milder damages are more challenging to study and knowledge of the long-term outcome in 
animal models is scarce. However, it is also known that slight damages, especially if repeated, 
may eventually lead to CKD in both rodents (Kennedy and Erlich, 2008) and humans (Waikar et 
al., 2008).
6.1.2  Kidney function and histology
S-creatinine and S-urea levels are the most widely used clinical markers of kidney function. 
Although insulin clearance and some other methods may be more accurate in estimating the 
GFR, they are to date not as easily available (Frank et al., 2012); thus, S-creatinine and S-urea 
levels were also used as primary markers of kidney function in our studies.
Kidney histology was examined with a microscope and morphological changes were 
assessed with a widely used ATN--scoring system adopted from Dragun et al. (2001). However, 
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it should be noted, that tubular necrosis in murine models is oft en more marked than is usually 
seen in human biopsy specimens (Kennedy and Erlich, 2008). 
6.2  Renoprotective effects of caloric restriction
CR is known to prolong the lifespan (Fontana et al., 2010) and has health-promoting eff ects in 
many chronic diseases (Colman et al., 2009; Fontana et al., 2010). It may also protect against 
more acute ischaemic injuries (Yu and Mattson 1999; Chandrasekar et al., 2001; Ahmet et al., 
2005).  Study I with CR was conducted to determine whether it protects against I/R-induced 
AKI and how it establishes its possible renoprotective eff ects at the cellular level. New potential 
targets for drug development were also of interest.
We found out that in an animal model, CR ameliorated I/R-induced AKI-related kidney 
dysfunction, ATN and nitrosative stress. It also induced SIRT1 expression and enhanced 
autophagy, as well as counteracting I/R-induced decreases in eNOS and PGC-1α expression levels 
in kidneys. We showed that I/R-induced AKI is associated with decreased expression of LC-3B, 
an important marker of autophagy, and CR counteracted this decrease. On the other hand, the 
autophagy inhibitor 3-MA counteracted the renoprotective eff ects of CR, which further suggests 
a crucial role for autophagy induction as a mechanism explaining the renoprotective eff ects of 
CR at the cellular level. It is known that induction of autophagy eliminates damaged organelles, 
e.g. dysfunctional mitochondria, which may otherwise increase the amount of hazardous waste 
products, such as ROS in the cell (Mizushima et al., 2008). Th e CR-induced attenuation of 
nitrosative stress seen in our study could thus be explained through enhanced autophagy and 
decreased amounts of dysfunctional mitochondria in the kidneys.  Jiang et al. (2012) recently 
showed that autophagy protects tubular cells in AKI.
It is worthwhile noting that in Study I, the SIRT1 inhibitor sirtinol did not infl uence renal 
function in CR rats with I/R injury. However, sirtinol could have failed to inhibit SIRT1 properly, 
because SIRT1 is located mainly in the nuclear compartment. A recent study  by Fan et al. (2013) 
strongly supports a protective role for SIRT1 in I/R-induced AKI,  and previous studies with 
CR have shown that in many tissues SIRT1 is activated  by CR and that this activation  may also 
be benefi cial  in the context of kidney diseases (Hallows et al., 2010). Furthermore, the SIRT1 
activator RSV attenuates I/R-induced AKI in rats (Bertelli et al., 2002; Chander and Chopra, 
2006), and activation of SIRT1 protects the mouse renal medulla from oxidative stress (He et 
al., 2010). Taken together, these notions support the idea that increased expression of SIRT1 has 
protective eff ects in the kidneys.
SIRT1 is located mainly in the nuclear compartment, but it also activates cytoplasmic 
enzymes, such as eNOS (Canto and Auwerx, 2012), which was upregulated by CR in our study, 
compared with the I/R group. CR is also known to activate eNOS (Nisoli et al., 2005). On 
the other hand, during CR eNOS induces SIRT1 gene expression, which forms an interesting 
positive regulatory loop (Nisoli et al., 2005; Canto and Auwerx, 2012). In our study, the further 
increase in SIRT1 expression by CR aft er kidney I/R injury could also have been mediated by NO 
produced by eNOS. Increased levels of NO have protective eff ects against I/R-induced AKI (Liu 
et al., 2007; Chen et al., 2008; Milsom et al., 2010), and also ischaemic preconditioning (IPC) 
protects kidneys against ischaemia by increasing NO through eNOS (Tawa et al., 2010; Tsutsui 
et al.2013).
Tsutsui et al. (2013) suggested that increased NO suppresses sympathetic nerve activity 
and reduces NA concentrations in the kidneys during the I/R period. NO also acts as a nitrite 
reductase under ischaemic conditions (Milsom et al., 2010), and other studies also indicate that 
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activating eNOS and increasing NO during I/R is benefi cial (Liu et al., 2007; Chen et al., 2008). 
It is thus possible that in our study, CR induced eNOS and increased the amount of NO, which 
protected the kidneys either through suppressing renal sympathetic nerve activity or reduction 
of nitrite. NO may also have acted as a vasodilator and thus preserved the blood fl ow to the 
postischaemic kidneys.
PGC-1α regulates mitochondrial biogenesis (Shoag and Arany, 2010), and induction of 
PGC-1α can decrease formation of ROS in the mitochondria (Patten and Arany, 2012). CR- 
induced eNOS also increases mitochondrial biogenesis (Nisoli et al., 2005).  Induction of the 
PGC-1α and eNOS levels by CR may thus also have decreased the amount of dysfunctional 
mitochondria and ROS in the kidneys in our study, which may also explain the attenuation of 
nitrosative stress.
6.3  Renoprotective effects of AICAR
In Study I we showed that I/R injury decreased the AMPK-P/AMPK ratio in the kidneys, 
compared with the sham-operated animals. CR protected the kidneys, but it did not manifest its 
eff ects through AMPK phosphorylation. However, other studies have indicated that activation of 
AMPK may be benefi cial during ischaemia (Bullough et al., 1994; Alkhulaifi  and Pugsley, 1995; 
Galinanes et al., 1995; Mathew et al., 1995; Peralta et al., 2001), which led us to test whether or 
not we could ameliorate kidney I/R injury through the AMPK activator AICAR.
In Study II preconditioning with AICAR indeed dose-dependently increased the amount 
of AMPK-P, improved kidney function, ameliorated  ATN, nitrosative stress and infi ltration 
of infl ammatory cells into the  kidneys aft er I/R-induced AKI. In I/R-induced AKI, the AMP/
ATP ratio in the kidneys increases and AMPK is activated within 1 min. Th e signifi cance of 
this activation has been unclear (Hallows et al., 2010). We showed that 24 h aft er I/R injury, 
AMPK phosphorylation is decreased. We also showed that phosphorylation of AMPK with 
AICAR attenuates I/R-induced AKI. AICAR was given i.v. 1 h before I/R injury, so it was likely 
that AMPK was already phosphorylated during the ischaemia, which suggests that activation of 
AMPK protects kidneys against I/R-induced AKI.
AICAR treatment also prevented the I/R-induced increase in renal SIRT1 expression. 
Increased SIRT1 expression may be a protective mechanism in I/R-induced AKI, but it is 
no longer necessary when AMPK is pharmacologically activated and nitrosative stress and 
accumulation of infl ammatory cells in the kidney are diminished.
AICAR also has other mechanisms of activity in addition to activation of AMPK. However, 
previous studies have shown that AICAR inhibits infl ammation (Peairs et al., 2009; Katerelos et 
al., 2010) and decreases the amount of ROS (Kim et al., 2008) through AMPK activation, which 
makes it likely that AMPK activation was also the main mechanism of activity in our study.
 Lee et al. (2009) recently showed that preconditioning with a single dose of AICAR 100 
mg/kg i.p. decreases S-creatinine and S-urea levels, as well as I/R-induced  ATN, and protects 
kidneys against subsequent reperfusion injury in SD rats. In their study, Lee et al. showed that 
AICAR dose-dependently phosphorylated AMPK in the kidneys and the renoprotective eff ects 
diminished when AMPK was inhibited. Th ese results suggest that AICAR was also the main 
protective agent in the study by Lin et al. (2004), in which combination therapy with AICAR and 
N-acetyl cysteine attenuated kidney I/R injury and improved kidney transplant function aft er 
cold preservation. Together, these studies suggest that AMPK activators are a potential new way 
to improve kidney function and attenuate ATN associated with I/R-induced AKI.
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6.4 Renoprotective effects of α2-adrenoceptor agonists
Studies I and II showed that activation of the metabolic sensors AMPK and SIRT1, as well as 
induction of autophagy, seems to be benefi cial in the context of I/R-induced AKI. Th ere is also 
some evidence from clinical studies that α2-AR agonists may protect kidneys (Kulka et al., 1996; 
Frumento et al., 2006). However, the mechanism of activity remains unclear, which led us to 
examine whether we could ameliorate kidney I/R injury by the α2-AR agonists Dex and/or Fado 
and whether they establish their possible renoprotective activities through AMPK and/or SIRT1 
and/or induction of autophagy. 
In Stydy III, Dex (10 μg/kg i.v. 1 h before ischaemia) preconditioning (but not 
postconditioning) indeed ameliorated kidney I/R injury and infl ammatory response. Dex 1 
μg/kg also attenuated  ATN, indicating that it also provided some renoprotection against I/R 
injury, although this was not enough to decrease the S-creatinine or S-urea levels. Dex did not 
establish its eff ects through AMPK or SIRT1, but it prevented I/R-induced decrease in LC-3B 
level, indicating that it boosted autophagy. Th is likely led to increased recycling of dysfunctional 
cellular organelles. Further studies are warranted to reveal the exact steps of the autophagic 
response that Dex aff ects. Th is would also shed more light on the overall pathogenesis of I/R-
induced AKI.
We also determined that the peripheral α2-AR agonist Fado treatment did not protect the 
kidneys, which indicates that the renoprotective eff ects of Dex were mediated (also) through 
central mechanisms. Nociceptive signalling activates the sympathetic nervous system and it is 
known that the renal sympathetic nervous system plays a crucial role in the development of I/R-
induced AKI (Fujii et al., 2003). Dex inhibits the release of NA in rat kidneys via activation of 
α2-ARs and reduces renal sympathetic nerve activity and plasma catecholamines by a central 
sympathoinhibitory eff ect (Xu et al., 1998; Taoda et al., 2001). Dex can therefore decrease the 
release of lactate from the tissues and facilitate the recovery from ischaemic events through these 
central sympatholytic properties, which may explain why Dex did and Fado did not protect 
the kidneys in our study (Willigers et al. 2003). However, local eff ects, such as stimulation of 
kidney α2B-ARs (Cussac et al., 2002) and α2-AR-mediated increase of NO in the glomerulus 
and proximal tubule (Th omson and Vallon, 1995; Nakayama et al., 2006),  may contribute to 
the renoprotective eff ects of Dex. Although Dex  may also have other eff ects, previous studies 
in which Dex protected tissues against ischaemia support the idea that it establishes its eff ects 
mainly through (central or peripheral) α2-AR stimulation (Gu et al., 2011b; Ibacache et al., 2012).
In Study III, Dex increased the active form of renal p38 MAPK. It is known that MAPKs 
can be activated through α2-ARs and that p38 MAPK protects the rat heart against I/R injury 
and promotes autophagy (Mocanu et al., 2000; Nakano et al., 2000; Bonventre, 2002; Cussac et 
al., 2002; Tang et al., 2008). Dex may have thus protected the kidneys through induction of these 
prosurvival kinase pathways. eNOS is a downstream mediator of p38 MAPK, and  expression 
of eNOS was also induced by Dex. As the study of Th omson and Vallon (1995) also indicates, 
α2-AR stimulation increases NO in the kidneys, which could explain why preconditioning with 
Dex protected the kidneys in our study.
Inhibition of necroptosis (a form of programmed necrosis) seems to be benefi cial in the 
context of RIR injury (Linkermann et al., 2012). We wanted to know whether Dex could also 
establish its activities through inhibition of necroptosis, so we performed an additional study 
with the death receptor-interacting protein kinase 1 (RIPK1) inhibitor, Nec-1. Nec-1 improved 
kidney function slightly, but not signifi cantly, and the renoprotective eff ects of Dex clearly 
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exceeded those of Nec-1. Cotreatment with Dex and Nec-1 also protected the kidneys, and 
Nec-1 slightly (but not signifi cantly) increased the renoprotective eff ect of Dex. Together, these 
results clearly show that Dex establishes its activities by means other than inhibition of renal 
necroptosis.
To further explore how Dex establishes its renoprotective eff ects, we performed a gene 
analysis of over 30 000 genes, which revealed that Dex also suppressed several signalling cascades 
promoting hypertrophic (‘hypertrophic cardiomyopathy’ pathway) and infl ammatory (TGFβ 
pathway) signalling in the kidneys (Spurgeon et al., 2005). Among the most interesting fi ndings 
was that Dex decreased CD44 mRNA. Cell adhesion and leukocyte infi ltration to injured tissue 
is mediated through the CD44 receptor (Chase et al., 2012). Dex decreased CD44 expression, 
which likely explains the reduction in ED-1-positive cells in the kidneys aft er I/R injury in our 
study. Th is is in line with the previous study by Gu et al. (2011b), which also indicates that Dex 
protects kidneys through suppression of the infl ammatory HMBG1-TLR4 pathway. In our study, 
Dex slightly decreased kidney TLR-4 expression aft er I/R injury, but the diff erence was not 
statistically signifi cant. However, it should be noted that the experimental settings were diff erent 
in these two studies. We also noted that Dex activated the organoprotective AHR pathway, which 
consists of a family of transcriptional regulators. Th ese regulators are activated in response to 
hypoxia and inhibit NF-кB, which in turn also decreases the infl ammatory response.
RAC signalling regulates production of ROS and over-expression of RAC worsens I/R 
injury in heart (Talukder et al., 2013). Interestingly, Shan et al. (2010) showed that disruption of 
RAC signalling protects against I/R injury in the heart. In our study, Dex decreased expression 
of several genes (Rab27b, Rasa2 and CDC42-binding protein kinase alpha isoform B) associated with 
RAC signalling, which may have also led to attenuation of kidney injury.
Moreover, many kinase signalling pathways, including p38 MAPK, seem to regulate Nrf2 
activation and facilitate its accumulation in the nucleus (Park et al., 2013). Nrf2, in turn, regulates 
the expression of several antioxidant and cytoprotective genes, and its activation is known to 
be protective during ischaemic AKI in mice (Liu et al., 2009). Th us, Dex may also establish 
some of its (antioxidative and anti-infl ammatory) protective eff ects through the α2B-adrenergic 
receptors-p38 MAPK-Nrf2 pathway. However, in this study Dex also attenuated I/R injury and 
decreased the amount of ED-1-positive cells. Th is is also likely to lead to reduced amounts of 
oxidative stress/ROS. N-acetylcystein reduces the amount of ROS, which further inhibits Nrf2 
activation (Leonard et al., 2006). Th us, the lower amount of ROS likely explains why the Nrf2-
signalling route was not activated in Study III.
Dex and Fado both lowered BP slightly when the preconditioning bolus was given, and 
continuous Dex infusions also caused a signifi cant drop. Fado and Dex have high affi  nity and 
full agonist effi  cacy for all three α2-AR subtypes and Fado is also a full agonist for α1-AR, which 
explains the observed transient rise in BP following the bolus (Lehtimäki et al., 2008). However, 
BP-dependent eff ects apparently played a minor role in Study III, because Dex infusion caused 
the highest hypotensive eff ect, but did not aff ect the S-creatinine levels. A haemodynamically 
induced IPC eff ect also seems unlikely, because the Dex 0.1 μg kg-1 min-1 infusion caused the 
largest hypotensive eff ect, but provided no renoprotection. However, autoregulation of blood 
fl ow in the kidneys functions until the MAP level drops below 75–80 mmHg (Sharfuddin and 
Molitoris, 2011), which suggests that an IPC eff ect was also possible in our study.
Th ese results suggest that central (and possibly also peripheral) α2-AR stimulation before, 
and during, the ischaemic period improves kidney function and attenuates I/R-induced 
development of ATN. Th is activity is mediated through preservation of normal levels of 
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autophagy, activation of the p38 MAPK-CD44 pathway and suppression of the proinfl ammatory 
signalling pathways in the kidneys.
6.5  Mechanisms of activity
Th e results of this thesis project show that I/R-induced AKI can be attenuated through CR, the 
AMPK activator AICAR and the α2-AR agonist Dex. Th e mechanisms of activity seem to diff er 
somewhat, but induction of autophagy, activation of AMPK, induction of SIRT1, PGC-1α and 
eNOS, as well as diminished infl ammatory signalling and reduced nitrosative/oxidative stress 
apparently play key roles (Diagram 6).
 
Diagram 6. Mechanisms of activity. Th e proposed mechanisms of how CR (Panel A), AICAR 
(Panel B) and Dex (Panel C) attenuate I/R-induced AKI. AHR = aryl hydrocarbon receptor, 
AICAR = 5-amino-4-imidazolecarboxamide riboside-1-β-D-ribofuranoside,  AKI = acute kidney 
injury, AMPK = adenosine monophosphate kinase, BP = blood pressure, CR = caloric restriction, 
Dex = dexmedetomidine, IPC = ischaemic preconditioning, I/R = ischaemia-reperfusion, NA = 
noradrenaline, NF-κB = nuclear factor kappa B, NO = nitric oxide, PGC-1α = peroxisome proliferator-
activated receptor gamma coactivator 1α, ROS = reactive oxygen species, SIRT1 = silent information 
regulator 1, SNS =  sympathetic nervous system, α2-AR = α2-adrenoceptor.
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6.6  Clinical relevance 
Th ese studies were undertaken to investigate the molecular and pathophysiological mechanisms 
of I/R-induced AKI. Since there is currently no specifi c treatment for I/R-induced AKI, the 
pathways involved may represent important targets for new drug development fi nding new ways 
to alleviate this injury. Th ese studies revealed that drugs mimicking the eff ects of CR, activating 
AMPK or acting through central α2-ARs are new potential ways to alleviate I/R-induced AKI 
and should be investigated more thoroughly.
CR provides protection against acute tissue injury in the kidneys (Mitchell et al., 2010), 
heart (Chandrasekar et al., 2001; Ahmet et al., 2005) and brain (Yu and Mattson, 1999) in various 
animal models. We showed that CR preconditioning ameliorates I/R AKI through enhanced 
autophagy and counteraction of I/R-induced decreases in the renal expression of eNOS and 
PGC-1α. Th e study by van Ginhoven et al. (2010) showed that CR is feasible with human 
transplant donors (van Ginhoven et al., 2010). However, in most clinical cases, CR and/or fasting 
before ischaemic injury could not be performed. In Finland, kidney transplants come mainly 
from brain-dead donors (CR preconditioning is no longer possible ), while with living patients 
increased catabolism (related to CR)  may lead to degradation of muscle proteins and impair 
the physical condition of (especially elderly) patients. It should be also noted that in kidney 
transplantation surgery kidney ischemia model is “cold ischemia”, whereas in our I/R model 
it was warm bilateral ischemia. Taken together, it is unlikely that these results have any direct 
clinical relevance in transplantation surgery, although further studies are warranted.
However, Study I provides new targets for drug treatments in I/R-induced AKI. Preservation 
of PGC-1α and eNOS levels with CR suggests that PGC-1α and eNOS activators may also be 
benefi cial in the treatment of I/R-induced AKI.  Drugs that directly increase mitochondrial 
biogenesis, enhance their functioning or capture mitochondrial ROS should also be studied 
further in the context of AKI. For example, the antioxidant α-lipoic acid seems a very promising 
agent (Wang et al., 2013). Induction of SIRT1, in turn, suggests that sirtuin activators may also 
be benefi cial in the context of AKI. Th is new class of drugs is currently being studied as a new 
potential way to treat type 2 diabetes (Pulla et al., 2012).
CR, as well as preconditioning with Dex 10 μg/kg i.v., also counteracted I/R-induced 
decrease in autophagy.  Th is preservation of normal autophagy levels likely helps to clear off  
hazardous waste products and facilitates the kidneys’ ability to recover aft er I/R-induced AKI. 
Th is suggests that inductors of autophagy may also be potential new drugs for the treatment of 
ischaemic injuries.
Study II also provides a new (in the context of renal ischaemia) potential target for drug 
development. AICAR phosphorylated AMPK dose-dependently and attenuated I/R-induced 
AKI. Th is suggests that activation of AMPK during ischaemia in the kidneys is a protective 
mechanism, and activators of kidney AMP kinase may thus represent a novel therapeutic 
approach to the treatment of AKI. Further studies with AMPK activators are warranted.
Dex is already in clinical use as a sedative for ICU patients who require only mild sedation, 
and some previous clinical studies indicate that it may also enhance renal function (Kulka et al., 
1996; Frumento et al., 2006). Our fi ndings that Dex downregulates the infl ammatory response 
and alleviates I/R-induced AKI support the use of Dex as a sedative, especially if the patient is 
susceptible to AKI.  A very recent study by Ji et al. (2013), in which the use of Dex was associated 
with a signifi cant reduction in the incidence of  AKI in patients undergoing cardiac surgery, 
supports this notion. Further clinical studies with α2-AR agonists are needed.
Discussion
49
Th e eff ect of these treatments on the long-term outcome of AKI should also be studied. It 
would be benefi cial to determine whether Dex treatment of ICU patients reduces the incidence 
and/or degree of subsequent CKD. Th e possible adverse eff ects appearing over a longer time 
period, as well as with repetitious treatments (e.g. with Dex), should be evaluated.
Th ese studies thus show that pharmacological agents mimicking the eff ects of CR, AMPK 




Th e aim of the present study was to increase our knowledge of the pathophysiological 
mechanisms underlying ischaemic AKI and to identify tentative drug targets for AKI. Using a 
well-established murine model of kidney I/R injury combined with biochemical, histological 
and immunohistochemical assessments of kidney damage, we evaluated the potential of three 
diff erent treatment strategies, namely preconditioning with CR, AMPK activation by AICAR, 
and α2-AR activation by the α2-AR agonist Dex, and examined their mechanisms of activity at 
the cellular level. Th e main conclusions of this series of experimental studies are as follows:
I Preconditioning of the kidneys by CR for 2 weeks ameliorates I/R injury-induced 
infl ammatory response, oxidative stress and ATN. Th e renoprotective eff ects of CR are 
mediated, at least in part, via induction of SIRT1 expression in the kidney, promotion of 
autophagy and counteraction of I/R-induced decreases in the expression of eNOS and PGC-
1α.
II Th e AMPK activator AICAR ameliorates I/R injury-induced AKI in a dose-dependent 
manner when given systemically. 
III  Preconditioning, but not postconditioning, with the centrally acting α2-AR agonist Dex 
ameliorates I/R injury-induced renal dysfunction, infl ammatory response and ATN. 
In contrast, neither pre- nor postconditioning with the peripheral α2-AR agonist Fado 
ameliorates kidney I/R injury, suggesting the importance of central α2-ARs.
Th ese fi ndings suggest that compounds mimicking the cellular eff ects of CR, activators of 
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